

POST-TRANSCRIPTIONAL REGULATION OF VIRULENCE GENES BY GLMY AND
GLMZ IN ENTEROHEMORRHAGIC *E. COLI*

APPROVED BY SUPERVISORY COMMITTEE

Vanessa Sperandio, Ph.D.

Lora Hooper, Ph.D.

Kevin Gardner, Ph.D.

Nicholas Conrad, Ph.D.

ACKNOWLEDGEMENTS

First and foremost I would like to thank my mentor, Dr. Vanessa Sperandio, for all her support during my graduate career. I also would like to thank the members of my lab, both past and present: Regan Russell, Dr. Melissa Kendall, Dr. Ben Habdas, Dr. Dave Hughes, Dr. Christopher Parker, Dr. Cristiano Moreira, Dr. Jackie Njoroge, Dr. Alline Pacheco, Dr. Dasha Terekhova, Dr. Meredith Curtis, Dr. Juan Hernandez-Doria, Dr. Kim Carlson, Y Nguyen, and Reed Pifer for all their help and making the lab an enjoyable place to work.

I would also like to thank my thesis committee, Dr. Lora Hooper, Dr. Nick Conrad, and Dr. Kevin Gardner for their guidance. I also would like to thank our collaborator, Dr. David Rasko, for his help in processing and analyzing RNA sequencing samples. I would also like to thank my friend and former fellow graduate student Dr. Robert Orchard, for helping to set up our live cell system.

I would also like to thank my family: my parents, Gary and Melva Gruber, my brothers, Patrick Hykkonen and William Gruber, and my sister, Brenda Frazier. I couldn't ask for a better family. I would also like to thank all my friends for making the last several years a wonderful time.

POST-TRANSCRIPTIONAL REGULATION OF VIRULENCE GENES
BY GLMY AND GLMZ IN ENTEROHEMORRHAGIC *E. COLI*

by

CHARLEY C. GRUBER

DISSERTATION

Presented to the Faculty of the Graduate School of Biomedical Sciences

The University of Texas Southwestern Medical Center at Dallas

In Partial Fulfillment of the Requirements

For the Degree of

DOCTOR OF PHILOSOPHY

The University of Texas Southwestern Medical Center at Dallas

Dallas, Texas

December, 2013

Copyright

by

Charley Gruber, 2013

All Rights Reserved

POST-TRANSCRIPTIONAL REGULATION OF VIRULENCE GENES
BY GLMY AND GLMZ IN ENTEROHEMORRHAGIC *E. COLI*

Charley C. Gruber, Ph.D.

The University of Texas Southwestern Medical Center at Dallas, 2013

Supervising Professor: Vanessa Sperandio, Ph.D.

Enterohemorrhagic *E. coli* O157:H7 (EHEC) is a major cause of foodborne illness and hemolytic uremic syndrome (HUS) throughout the world. One of the major virulence factors in this pathogen is a type III secretion system (T3SS) encoded by the locus of enterocyte effacement (LEE). EHEC uses this proteinaceous needle to inject effector proteins into host cells to hijack various host cellular processes, as well as the translocation and insertion of the translocated intimin receptor (Tir) into the host cell membrane. The bacterial adhesin intimin then binds to Tir, allowing EHEC to tightly adhere to the host cell's membrane (109). Tir also indirectly recruits another bacterial effector EspFu, which induces actin polymerization. This causes the formation of the characteristic pedestal that cups the bacterial cell. This process from the assembly of the needle apparatus to the formation of the pedestal must be tightly regulated both transcriptionally and post-transcriptionally.

The two two-component systems QseEF and QseBC have been previously shown to regulate various virulence genes. We established that these systems both regulate the transcription of the small RNA (sRNA) *glmY*. GlmY is known to stabilize another sRNA, GlmZ, which activates the translation of glucosamine synthetase (GlmS) (72). Here we show that GlmY and GlmZ are also important players in the post-transcriptional regulation of virulence genes in EHEC.

The transcription factor QseF is required for the expression of *EspFu* and thus pedestal formation. This defect can be complemented by overexpression of either GlmY or GlmZ and is not at the transcriptional level. Instead, the expression of *espFu* requires a processing event that is QseF dependent. We have shown that GlmZ also post-transcriptionally regulates two of the operons of the LEE, *LEE4* and *LEE5*. Both of these operons are transcribed from a single promoter, but there is a processing event that separates the first gene of the operon from the rest that requires the endoribonuclease RNase E. Overexpression of either sRNA results in the downregulation of the latter fragment of both the *LEE4* and *LEE5* operons. In the case of *LEE4*, this is through direct binding of GlmZ to a region within the *LEE4* mRNA.

We also investigated the global role of GlmY and GlmZ in EHEC through microarrays and RNA sequencing of the knockout strains. Aside from the LEE, GlmZ also regulates curli which are used to facilitate bacteria attachment to host cells. These data show that GlmZ has been co-opted into being an important regulator of virulence genes in EHEC.

TABLE OF CONTENTS

ABSTRACT	v
PRIOR PUBLICATIONS	x
LIST OF FIGURES	xi
LIST OF TABLES	xiii
LIST OF DEFINITIONS	xiv
CHAPTER ONE: LITERATURE REVIEW	1
HISTORY	1
EPIDEMIOLOGY AND CLINICAL PRESENTATION	2
VIRULENCE FACTORS	4
Locus of Enterocyte Effacement and the EHEC Pedestal	4
Regulation of the LEE	7
Shiga Toxin.....	8
Other Virulence Factors	10
ANIMAL MODELS	11
INTERKINGDOM SIGNALING	12
History.....	12
AI-3 and the Qse System	13
QseF	15
RNA REGULATION IN BACTERIA	17
History and Early Examples	17
Riboswitches and cis-acting elements	17
Cis-encoded RNAs.....	22
Trans-encoded RNAs.....	23
Other Regulators	25
GLMYZ	26
Glucosamine metabolism.....	26
Regulation of GlmS	27
GlmY and GlmZ	28

CHAPTER TWO: OVERALL OBJECTIVE AND SYNOPSIS	30
CHAPTER THREE: METHODOLOGY	32
STRAINS, PLASMIDS, AND GROWTH CONDITIONS	32
RECOMBINANT DNA TECHNIQUES	32
RNA PURIFICATION	34
NORTHERN BLOT	35
QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION	35
REPORTER ASSAYS.....	36
OPERON ANALYSIS BY RTPCR.....	37
PROTEIN PURIFICATION.....	37
ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSA).....	38
WESTERN BLOTS	39
CONGO RED PLATES.....	39
CELL CULTURE AND FAS	40
TEMPERATURE SENSITIVE RNASE E.....	40
LIVECELL IMAGING.....	41
MICROARRAY GLOBAL ANALYSIS	41
RNA SEQUENCING.....	42
CHAPTER FOUR: POST-TRANSCRIPTIONAL CONTROL OF MICROBIAL- INDUCED REARRANGEMENT OF HOST CELL ACTIN	47
INTRODUCTION	47

RESULTS	50
Transcriptional Regulation of <i>glmY</i> and <i>glmZ</i>	50
Regulation of EspFu by QseF	53
The role of GlmY and GlmZ in pedestal formation	57
Post transcriptional regulation of <i>LEE5</i> and <i>LEE4</i> by GlmY and GlmZ.....	63
 DISCUSSION	 70
Post transcriptional regulation of bacterial virulence gene expression.....	71
Co-option of a metabolic regulatory pathway	72
Timing and dynamics of infection	72
 CHAPTER FIVE: POST-TRANSCRIPTIONAL REGULATION BY GLMY AND GLMZ IN ENTEROHEMORRHAGIC E. COLI	 74
 INTRODUCTION	 74
 RESULTS	 75
Global targets of GlmY and GlmZ	75
RpoS.....	77
Regulation of Curli by GlmZ.....	84
Regulation of NleA.....	85
 DISCUSSION	 87
GlmYZ and RpoS	87
GlmY without GlmZ.....	88
Regulation of Other Virulence Genes by GlmYZ	89
 CHAPTER SIX: CONCLUSIONS AND FUTURE DIRECTIONS	 90
 CONCLUSIONS.....	 90
The role of RpoS in GlmYZ regulation	90
Post transcriptional regulation of bacterial virulence genes	91
GlmY vs. GlmZ	93
Tying metabolism to virulence	94
Timing is everything	95
 FUTURE DIRECTIONS	 97
 REFERENCES	 102

PRIOR PUBLICATIONS

Gruber CC, Sperandio V. Post-transcriptional Control of Microbial-Induced Rearrangement of Host Cell Actin. *mBio*. Submitted.

Njoroge JW, **Gruber CC**, Sperandio V. The interacting Cra and KdpE regulators are involved in the expression of multiple virulence factors in Enterohemorrhagic *Escherichia coli*. *J Bacteriol*. 2013 Jun;195(11):2499-508.

Charley Gruber and Vanessa Sperandio. Regulation in response to host-derived signaling molecules. In *Regulation of Bacterial Virulence*, Michael Vasil and Andrew Darwin (ed). ASM Press. 2012.

Kendall MM, **Gruber CC**, Parker CT, Sperandio V. Ethanolamine controls expression of genes encoding components involved in interkingdom signaling and virulence in enterohemorrhagic *Escherichia coli* O157:H7. *MBio*. 2012 May 15;3(3).

Kendall MM, **Gruber CC**, Rasko DA, Hughes DT, Sperandio V. Hfq virulence regulation in enterohemorrhagic *Escherichia coli* O157:H7 strain 86-24. *J Bacteriol*. 2011 Dec;193(24):6843-51.

LIST OF FIGURES

Figure 1.1: Epidemiology of 2012 EHEC Outbreak.....	2
Figure 1.2: Course of EHEC infection.....	3
Figure 1.3: EHEC Pedestal	4
Figure 1.4: LEE T3SS.....	5
Figure 1.5: Pedestal Formation.....	7
Figure 1.6: Crystal structure of Shiga toxin 2.....	9
Figure 1.7: Diagram of the Qse cascade in EHEC	15
Figure 1.8: T-Box	19
Figure 1.9: B12 Riboswitch.....	21
Figure 1.10: sRNA regulation.....	22
Figure 1.11: GadY	23
Figure 1.12: Glucosamine pathway	27
Figure 1.13: GlmS-GlmZ interaction.....	28
Figure 1.14: GlmY and GlmZ.....	29
Figure 4.1: QseF and QseB regulation of glmY	52
Figure 4.2: QseB binding sites in EHEC, EPEC and K-12	53
Figure 4.3: Post-transcriptional regulation of EspFu.....	55
Figure 4.4: GlmY and GlmZ regulation of AE lesion formation and the LEE genes	58
Figure 4.5: GlmY and GlmZ regulation of AE lesion timing and dynamics.....	60
Figure 4.6: GlcNac and GlmS are not involved in the AE lesion GlmY/GlmZ- dependent phenotype.....	61

Figure 4.7: GlmY and glmZ regulation og glmS in EHEC and K-12 MC4100	62
Figure 4.8: GlmY and GlmZ regulation of the <i>LEE5</i> operon	64
Figure 4.9: GlmY and GlmZ regulation of the <i>LEE4</i> operon	67
Figure 4.10: GlmZ acts in an RNase E independent manner	69
Figure 4.11: Model of GlmY and GlmZ virulence regulation	70
Figure 5.1: RNA seq for Δ <i>glmY</i> and Δ <i>glmZ</i>	77
Figure 5.2: Regulation of <i>rpoS</i> in Δ <i>glmY</i> and Δ <i>glmZ</i>	79
Figure 5.3: Comparison of Δ <i>glmZ</i> and Δ <i>rpoS</i>	81
Figure 5.4: Heatmap of Δ <i>glmY</i> and Δ <i>glmZ</i> vs Δ <i>rpoS</i>	83
Figure 5.5: Regulation of curli by GlmYZ.....	84
Figure 5.6: Regulation of <i>nleA</i> by GlmYZ.....	85
Figure 6.1: Virulence gene regulation by GlmYZ	93
Figure 6.2: QseEC cascade and GlmYZ	97

LIST OF TABLES

Table 3.1: Strains	44
Table 3.2: Plasmids	44
Table 3.3: Primers	45
Table 5.1: Table of changes in gene expression in $\Delta glmY$ and $\Delta glmZ$ vs $\Delta rpoS$	82

LIST OF DEFINITIONS

86-24	Enterohemorrhagic <i>E. coli</i> wild-type strain 86-24
Eae	Intimin
<i>E. coli</i>	<i>Escherichia coli</i>
EHEC	Enterohemorrhagic <i>E. coli</i>
EPEC	Enteropathogenic <i>E. coli</i>
EspA	<i>E. coli</i> secretion protein A
FAS	Fluorescent actin staining
GlmS	Glucosamine synthetase
GlmY	Regulator of glucosamine synthetase Y
GlmZ	Regulator of glucosamine synthetase Z
HUS	Hemolytic uremic syndrome
LEE	Locus of Enterocyte Effacement
MC4100	<i>E. coli</i> K12 strain MC4100
MG1655	<i>E. coli</i> K12 strain MG1655
mRNA	Messenger RNA
RpoA	RNA polymerase subunit α
sRNA	Small RNA
Stx	Shiga toxin
Tir	Translocated intimin receptor

CHAPTER ONE

Literature Review

HISTORY

Escherichia coli, a member of the Enterobacteriaceae family in the γ -Proteobacteria phylum, was first isolated by the German bacteriologist Theodor Escherich in 1885 (61). *E. coli* is a Gram negative, motile, facultative anaerobe rod that is typically found as a commensal in the mammalian colon. It has been used as one of the primary model organisms and is used extensively in molecular biology and biotechnology.

Even though many strains are harmless or even beneficial to the host, others have acquired different virulence factors through horizontal gene transfer that allow them to cause a wide array of different diseases in humans (102). One of these, enterohemorrhagic *E. coli*, or EHEC, was first identified as a human pathogen in 1982 following an outbreak of food poisoning in which 47 people were hospitalized with a nonfebrile illness characterized by bloody diarrhea. The outbreak was linked to the consumption of undercooked hamburger meat from McDonald's restaurants in Oregon and Michigan and the causative agent was found to be a noninvasive and nontoxigenic variant of *E. coli* with the serotype O157:H7, with the O referring the O chain of the lipopolysaccharide (LPS) and H the flagellar antigen (188). This dissertation focuses on studying the EHEC strain 86-24 which was isolated from a patient in 1986 (3). Since its initial discovery, EHEC has been recognized as a major cause of hemorrhagic colitis throughout the world.

EPIDEMIOLOGY AND CLINICAL PRESENTATION

EHEC is a foodborne pathogen that is normally spread through the consumption of contaminated meat or produce as well as many other foods such as cider, juice, or milk (34, 73, 132, 141). The reservoirs are ruminants such as cattle, deer, sheep, or goats which are asymptotically infected with the organism, and direct human infection from these animals such as from petting zoos has also been reported (32, 115, 253). EHEC has a low infectious dose of 10-100 cfus which contributes to its ability to cause large outbreaks (12). The CDC estimates there are 96,000 EHEC O157 infections every year in the US and 170,000 non-O157 serotypes with an average of 30 deaths (198). In 2012, there were three outbreaks of EHEC, one of which was caused by O157 that was linked to the consumption of organic spinach (Figure 1.1). In this outbreak, 33 people were known to be infected with 46% being hospitalized and 2 cases progressing to hemolytic uremic syndrome (HUS) with 0 deaths.



Figure 1.1: Epimeology of 2012 EHEC Outbreak. Map showing the cases per state of the 2012 EHEC O157 outbreak. Image courtesy of the CDC website

In a typical case symptoms begin within 3-8 days following consumption of contaminated food or drink starting with severe abdominal cramps and watery diarrhea, 50% of the patients experience extreme nausea and vomiting. Within 1-5 days later this progresses to bloody diarrhea in most patients which usually lasts 2-4 days after which the patient typically recovers (16, 199). While the actual infection is resolved within a week from the onset of symptoms, 2-14 days later 5 to 10% of cases develop hemolytic uremic syndrome (HUS). (40, 179) (Figure 1.2). HUS is characterized by hemolytic anemia, thrombocytopenia and renal failure, leading to death in 5% of the cases (173). Even if the patient survives HUS, there are many sequelae, with 50% experiencing chronic renal or neurological problems (199, 211).




Figure 1.2: Course of EHEC infection. Diagram showing the time course of EHEC infection and probability of advancing to the next stage

Clinical diagnosis of EHEC is typically performed by plating stool samples from patients on sorbitol-MacConkey agar. EHEC, unlike other varieties of *E. coli*, is unable to ferment sorbitol, and will not turn red on this media (129). Isolates can also be confirmed by ELISA using anti-O antigen or anti-Shiga toxin antibodies or by PCR (169). Recommended treatment for EHEC infection is largely supportive and consists of providing fluids and electrolytes. The use of antibiotics is controversial, and has been linked to a greater risk of

HUS due to the increased expression of Shiga toxin (168). The treatment for HUS largely consists of managing the anemia, hypertension, and the loss of kidney function through dialysis.

VIRULENCE FACTORS

Locus of Enterocyte Effacement and the EHEC Pedestal

When EHEC infects its host, the bacterium attaches to an epithelial cell through an attaching and effacing (AE) lesion where it rearranges the host's cytoskeleton, which leads to the effacement of the microvilli and the formation of a characteristic pedestal structure that cups the bacterial cell (Figure 1.3).



Figure 1.3: EHEC Pedestal. Scanning electron micrographs of an EHEC (left) and the closely related EPEC (right) pedestals on epithelial cells. (102, 116).

Most of the genes responsible for this phenotype are located in a 35kb pathogenicity island called the locus of enterocyte effacement (LEE) (Figure 1.4) (133). The LEE contains five major operons, *LEE1-5*, that encode a type three secretion system (T3SS), as well as many of

its regulators and several effector proteins (27, 58, 136). The first operon (*LEE1*) contains *ler*, which encodes the master regulator of the LEE (136). Additionally, *LEE1* along with *LEE3* encode the EscRSTUV inner membrane complex of the T3SS which is assembled in a sec-dependent manner. *LEE2* encodes the outer membrane secretin EscC and the periplasm-spanning protein EscJ (44, 67). The *LEE4* operon encodes the needle protein EscF (255). However, unlike most other T3SS, this needle is then extended through the addition of an EspA filament (*LEE4*) that is up to 1 μ m in length (45, 116, 167). This filament structure is then capped with the EspDB translocon pore that inserts into the host cell membrane (Figure 1.4) (92, 117).




Figure 1.4: LEE T3SS. Cartoon diagram of the structure of the LEE needle apparatus (A) (167). Scanning electron micrograph showing the EspA filament extending from an EPEC cell (B) (116). Schematic of the LEE pathogenicity island (C) (190).

In addition to the structural proteins of the LEE, there are other proteins involved in the formation and function of the needle apparatus. EscN encoded by the *LEE3* operon is the ATPase that unfolds the effector and translocon proteins so that they can then pass through the needle and filament (7). SepD (*LEE2*) and SepL (*LEE4*) together regulate the formation of the EspADB translocon and the hierarchy of effector secretion. SepL directly binds to the effector Tir and is required for the formation of the translocon (48, 158, 248). The LEE also contains six effector proteins. EspG destabilizes the Golgi apparatus and affects microtubule assembly (39, 83, 203, 233). EspH inhibits Rho-GEFs and is involved in rearrangement of the host cytoskeleton (256). Map is a Rho-GEF mimic and is a member of the WxxxE family of effectors (4, 162). The exact function of EspF is unknown, but it has been implicated in the depletion of host mismatch repair proteins and the induction of apoptosis of infected cells (127, 264). The effector EspZ promotes host cell survival by interacting with CD98 in addition to regulating the translocation of other effectors (17, 192, 206). The *LEE5* operon encodes Tir, the translocated intimin receptor and the intimin adhesin (58). In addition to these effectors the LEE also contains various chaperones for many of the proteins secreted through the T3SS, including CesT for Tir and Map (42, 55), CesF for EspF(57), CesD and CesD2 for EspD and EspB (153, 244) and CesAB for EspA and EspB (43).

AE lesion formation requires the T3SS, as well as two effectors Tir and EspFu, and the adhesin intimin, encoded by the *eae* gene in *LEE5*. This outer membrane protein is secreted through the sec system and has been shown to be necessary for colonization (51, 52, 87). The effector Tir is able to insert itself into the host cell membrane where it can interact

with intimin on the bacterial cell, allowing the bacterium to tightly adhere to epithelial cells (109). Tir then recruits the host protein insulin receptor tyrosine kinase substrate (IRTKS) which then recruits the non-LEE encoded effector EspFu/TccP (28, 66, 239). EspFu then recruits N-WASP and the actin nucleating complex Arp2/3 which leads to the polymerization of actin beneath the bacteria cell (Figure 1.5).




Figure 1.5: Cartoon diagram of the proteins required to form the AE lesion beneath EHEC

Regulation of the LEE

The LEE is tightly regulated at multiple levels. The entire pathogenicity island is extremely AT-rich and is repressed by the global regulator H-NS (227). *Ler*, the *LEE1* encoded master regulator, antagonizes this repression and acts as a positive regulator of the rest of the LEE (27). There are several known regulators of *ler* transcription, including Cra, KdpE (155), QseA (108, 209), EutR (126), Fis (69), GadE (99), Hha (208), EivF (263), and IHF (63). GrlA and GrlR are two other LEE encoded regulators of the LEE that activate and

repress LEE expression, respectively (11, 94, 97, 194). The global regulator of stationary phase in *E. coli*, the sigma factor RpoS, is also known to act as a repressor of the LEE (50).

There is significant post-transcriptional control of the LEE as well. Mutants of the RNA chaperone Hfq have differential expression of virtually every virulence gene, although whether the effect is positive or negative depends on the strain. In 86-24, the strain used in this study, Hfq is required for the expression of virulence genes with the knockout having a severe defect in their expression (81, 107, 205). Several known regulators of the LEE are under post-transcriptional control. RpoS is tightly regulated post-transcriptionally by three different small RNAs (sRNAs), RprA, DsrA, and OxyS (186). The *grlRA* operon is under post-transcriptional control by some yet unknown sRNA. Additionally, the *LEE4* operon undergoes a RNase E dependent processing event with the first gene, SepL, being processed off the rest of the operon (123). The RNA binding protein and global regulator CsrA has also been reported to regulate *LEE1* and *LEE4* (19). This high level of regulation at every level allows for tight spatial and temporal control of LEE expression.

Shiga Toxin

The primary cause of morbidity and mortality from EHEC infection is renal failure following HUS, and the virulence factor responsible for this is Shiga toxin (Stx) (103). This toxin has two major subtypes, Stx1 and Stx2 that are sero-specific. In EHEC, these toxins are encoded in prophages with some strains being capable of carrying multiple varieties

(223). Stx2 is 1000 times more cytotoxic than Stx1 and patients infected with strains encoding this toxin are more likely to develop HUS (164).

Stx is a classic AB exotoxin. The A subunit is the enzymatically active portion, while the B subunit acts by the binding to the toxin receptor. Stx has a 1:5 stoichiometric ratio of A:B subunits (Figure 1.6). The B subunit binds to the glycolipid receptor globotriaosylceramide (Gb3), and causes the toxin to be internalized by clathrin-dependent endocytosis (111, 120). Gb3 is abundant on kidney cells, which leads to them being targeted by Shiga toxin, causing their death and HUS. Once internalized the A subunit acts as an N-glycosidase that specifically cleaves an adenine from the 18S rRNA resulting in a shutdown of protein translation followed by cell death (59, 197).




Figure 1.6: Crystal structure of Shiga toxin 2. Ribbon diagram of Stx2. The A subunit is red and the five B subunits are shown blue. (62).

The *stxAB* genes are located in the late genes of a λ prophage. These genes are not expressed under normal conditions due to the phage cI repressor that maintains the phage in a lysogenic state (151, 174, 177). If the bacterial cell encounters extreme stresses that cause DNA damage, the SOS response is triggered (178). Damage to the chromosome produces ssDNA that activates the RecA protease. RecA then is able to bind to the repressor LexA, leading to its self-cleavage and promoting the expression of DNA repair enzymes (121). RecA also cleaves the phage-encoded repressor cI (191), resulting in the prophage entering its lytic cycle that leads to the production and release of Shiga toxin (237). Treatment with various kinds of antibiotics such as beta-lactams or fluoroquinolones is capable of inducing the SOS response in *E. coli*, triggering the lytic cycle of a λ phage (105). Hence the use of antibiotics during an EHEC infection is controversial, and is believed to increase the risk of HUS (195).

Other Virulence Factors

In addition to the LEE and the previously mentioned effector EspFu, EHEC contains at least 40 other effectors (231). Many of these, including EspFu, are encoded within cryptic prophages. This suggests that many of them were recently acquired through horizontal gene transfer and there is potentially even greater diversity of effectors in the *E. coli* pangenome (231). Fourteen of these effectors belong to the NleG of E3 ubiquitin ligases, although their targets are not yet known (258). The effector NleA disrupts tight junctions, and has been

shown to be important for virulence in the related attaching and effacing pathogen *Citrobacter rodentium* (75, 112, 148, 228).

EHEC also contains the 93kb F-like pO157 plasmid (24). This plasmid encodes several known virulence factors including a hemolysin (15, 200), a catalase (23), a type II secretion system (201), ToxB (226), a metalloprotease StcE (118), and a serine protease called EspP (22). The EHEC LPS O-antigen is required for full virulence in various animal models and likely protects the bacteria from the host (104, 144).

In addition to the tight adherence provided by the Tir-Intimin interaction, there are many other potential adherence factors whose role in virulence is largely unknown. EHEC produces curli encoded by the *csg* genes. Curli have been shown to mediate attachment to abiotic surfaces, as well as increase attachment to epithelial cells *in vitro* (113, 170). EHEC also encodes a type IV pilus called the hemorrhagic coli pili (HCP) that binds to host extracellular matrix proteins, and contributes to biofilm formation by mediating bacterial-bacterial interaction (259). There are many other potential fimbriae and adhesins in the EHEC genome; however, most of these are not expressed under any known laboratory condition and many are likely not functional (124).

ANIMAL MODELS

There are several animal models that have been used to study EHEC pathogenesis, including mice, rabbits, chickens, dogs, pigs, cows, ferrets, macaques and baboons (137). One of the most useful of these is the infant rabbit model, where 3-day-old rabbits are

infected. These animals are subsequently colonized and experience diarrhea, colonic inflammation and death (166).

There are several different varieties of mouse models such as conventional, antibiotic treated, or germ-free, however, these are of limited utility in studying EHEC infection. While the mice are susceptible to Shiga toxin, EHEC does not form attaching and effacing lesions in the mouse intestines or cause hemorrhagic colitis (53, 243). There is a closely related organism *Citrobacter rodentium* that is a natural mouse pathogen. This organism also contains the LEE and is capable of forming AE lesions on epithelial cells in the mouse colon. C3H/HeJ mice are highly susceptible to infection and will die after oral challenge with *Citrobacter* (254). Because of the ease of care for mice, *Citrobacter* provides a useful proxy to study EHEC pathogenesis *in vivo*. The genetic tractability of mice also allows for the study of the host immune response to an AE lesion forming pathogen.

INTERKINGDOM SIGNALING

History

Cell to cell signaling in bacteria was first described in the marine organism *Vibrio fischeri* (84, 150). This bacterium is a symbiont of the Hawaiian bobtail squid, where it resides in a special light organ. It is able to mask the squid's silhouette at night by producing light, thus protecting it from predators. *V. fischeri* governs its production of light through quorum sensing. The signal, an acyl homoserine lactone (AHL) called autoinducer 1, is produced by the LuxI enzyme. AI-1 diffuses into the environment, and when it reaches a

critical threshold, it is able to bind to the LuxR transcription factor that then activates the luciferase genes required for light production (60). This system ensures light is only produced by the bacteria at high population densities such as those in the squid's light organ at night.

Since its discovery, homologues of the LuxRI system have been found in many other species of bacteria. Different species produce AHLs of varying acyl-chain length in order to create specificity towards their particular LuxR receptor (252). The human pathogen *Pseudomonas aeruginosa* has two complete LuxRI systems (LasRI and RhlRI), and an orphan LuxR (QscR) (64, 215). These systems have been shown to regulate adhesion, biofilm formation, and virulence (193, 215). *E. coli* and *Salmonella enterica* have an orphan LuxR homologue SdiA, but they do not have a homologue for the LuxI synthase (2, 140). Orphan systems such as this have been shown to be involved in interspecies communication (64).

A second quorum sensing system called AI-2 was discovered as a LuxRI independent system that regulates bioluminescence in *Vibrio harveyi* (13). AI-2 is a furanosyl borate diester in *V. harveyi* and a tetrahydroxytetrahydrofuran in *E. coli* and *Salmonella* that is produced as a byproduct of the activated methyl cycle and is produced by the enzyme encoded by the *luxS* gene (143, 224). In *E. coli* and *Salmonella*, AI-2 has been shown to regulate its uptake system encoded in the *lsr* operon (225). Investigation into the role of AI-2 signaling has been complicated by the important role of LuxS in cell metabolism, and the presence of the sRNA *micA* which is adjacent to the *luxS* locus (114, 171).

AI-3 and the Qse two-component systems

AI-3, a third quorum sensing signal, is produced by various bacterial species including *E. coli*, *Salmonella*, *Citrobacter*, *Klebsiella*, *Enterobacter*, *Bacteriodes*, and *Bifidobacterium*. Little is known about this signaling molecule, but it is distinct from AI-1 and AI-2. In EHEC the AI-3 system has been shown to regulate expression of the LEE and the flagella (246, 247), and its receptor is QseC (37). In addition to sensing this bacterial signaling molecule, QseC is also able to sense the host hormones epinephrine and norepinephrine (37).

QseC is a histidine kinase encoded in an operon with its cognate response regulator QseB. It responds to AI-3, epinephrine, and norepinephrine by increasing its autophosphorylation followed by transferring of the phosphate to a response regulator. QseC is a promiscuous kinase, and is capable of phosphorylating three response regulators, its cognate QseB, KdpE, and QseF (90). QseB regulates the expression of the flagella regulon by binding to the promoter of the master regulator *flhDC*, with phosphorylated QseB activating transcription while unphosphorylated QseB acts as a repressor. KdpE activates the transcription of *ler* by working in concert with the metabolite regulator Cra (Figure 1.7) (155).

In addition to QseC, there is another histidine kinase that senses epinephrine, QseE, which is encoded in the *qseEGFglnB* operon. QseE is also capable of sensing sulfate and phosphate and is only known to phosphorylate its cognate response regulator, QseF (182).

This operon also contains the outer membrane lipoprotein QseG, the PII nitrogen regulating protein GlnB, and QseE's cognate response regulator QseF (182, 183). QseF is a promiscuous response regulator and is capable of being phosphorylated by multiple histidine kinases, including BaeS, EnvZ, RstB, UhpB, as well as QseC, and QseE (Figure 1.7) (261).




Figure 1.7: Diagram of the Qse cascade in EHEC. QseC senses AI-3, epinephrine, and norepinephrine and is capable of phosphorylating three response regulators KdpE, QseB, and QseF. QseE senses epinephrine, sulfate, and phosphate and can phosphorylate QseF. KdpE activates transcription of the LEE, QseB regulates the flagella, and QseF is required for pedestal formation

QseF

QseF is a σ^{54} -dependent transcriptional activator. This family of transcription factors is a distinct class that recruits the alternative σ^{54} RNA polymerase holoenzyme (139). In *E.*

coli, σ^{54} regulated genes are canonically involved in nitrogen assimilation, however it has also been implicated in the regulation of virulence in EHEC and other organisms (5, 82, 185, 189). The σ^{54} promoter sequence contains conserved -24/-12 regions where the RNA polymerase binds, distinct from the -35/-10 sequences of the σ^{70} housekeeping RNA polymerase (229). Unlike the other sigma subunits of RNA polymerase, σ^{54} RNA polymerase lacks an ATPase, and is unable to form the DNA open complex and initiate transcription, which results in all σ^{54} promoters being by default 'off.' Consequently, σ^{54} -dependent transcriptional activators, or bacterial enhancer binding proteins (bEBP), contain an AAA+ ATPase domain in order to melt the DNA helix and initiate transcription after they recruit the σ^{54} RNA polymerase. These transcription factors form a hexameric ring that binds to DNA further upstream than traditional bacterial transcription factors, up to 800 bp from the transcription start site. This distance means the DNA must loop for the transcription factor to interact with the RNA polymerase (26, 33).

Initial work found that QseF is required for the expression of the effector EspFu. Mutants are unable to form pedestals on HeLa cells and this could be complemented by the expression of EspFu *in trans* from a plasmid (183). This regulation is not direct as EspFu does not have a σ^{54} promoter and QseF does not bind to the *espFu* promoter region. The intermediate factor in this regulation is not known. However, QseF was later reported to directly activate the transcription of the gene encoding the small RNA *glmY* located upstream of the *qseEGFglnB* operon (184).

RNA REGULATION IN BACTERIA

History and Early Examples

RNAs have long been known to be important regulators, and before eukaryotic microRNAs (miRNAs) and small interfering RNAs (siRNAs) were discovered, examples of regulatory RNAs were known in bacteria. The first such example was RNAI encoded in ColE1 replicon plasmids. Another RNA, RNAII, serves as a primer that initiates replication of the plasmid. RNAI base pairs with RNAII, preventing it from binding to the plasmid DNA thus halting its replication (222, 232). RNAI is also negatively regulated by the plasmid encoded protein PcnB, which polyadenylates the RNA leading to its degradation (85, 260). The second discovered example came from the transposon Tn10 where a RNA encoded within the transposon blocks the translation of the transposase mRNA (214). The first chromosomally encoded regulatory RNA discovered was *micF*, which blocks the translation of the porin *ompF* (145). Since these early discoveries many more sRNAs have been reported that can be categorized into several major groups.

Riboswitches and cis-acting elements

The first major variety of RNA regulators are those that are encoded within the mRNA they regulate. The classic *trp* operon attenuator belongs to this class. This operon encodes the genes for tryptophan synthesis and a leader peptide. When tryptophan levels in the cell are high, charged *trp* tRNAs are common, leading to translation of the leader peptide. Since transcription and translation are coupled, the active translation of the mRNA allows for

a hairpin to form which halts transcription. When tryptophan levels are low, translation of the leader peptide stalls, and the unprotected reading frame prevents the formation of the hairpin allowing transcription of the tryptophan synthesis genes to continue (18). Similar attenuation systems exist in other amino acid synthesis genes (138).

T-boxes, a related but distinct system, exist in Gram-positive bacteria where they are typically used to regulate amino acid synthesis and aminoacyl tRNA synthetase. In this system, uncharged tRNAs directly bind to the 5' UTR and prevent the formation of the anti-terminator, while charged tRNAs cannot bind, terminating transcription of the operon (Figure 1.8) (76).




Figure 1.8: T-Box. Diagram showing the secondary structure of a T-Box element (A). The T-box element that forms the terminator is shown in blue. Upon binding to uncharged tRNAs the anti-terminator is stabilized, allowing transcription to continue (B) (76).

RNA thermometers are a fairly simple way to regulate gene expression. At low temperatures, a hairpin structure forms, blocking the ribosome binding site (RBS). When the bacterium is exposed to higher temperatures, this hairpin melts, revealing the RBS and allowing translation. This system is often used to regulate heat shock proteins and virulence genes (149).

Riboswitches are generally 5' UTRs that are capable of binding small molecules, although that term can also apply to the previously described systems. A riboswitch consists of two elements, an aptamer region and the expression platform. The aptamer region is the highly conserved ligand binding region that transmits the environmental signal to the expression platform through allosteric changes that alter base pairing. Most riboswitches modulate translation by controlling access to the ribosome binding site; however, a few regulate transcription through the formation of a terminator loop (128). Riboswitches are modular, with the same aptamer region being capable of controlling different expression platforms. For example, the cobalamin riboswitch that senses the coenzyme B12 acts as a transcriptional terminator of the *btuB* operon in Gram-positive bacteria, and translational activator of the *cob* genes in Gram-negatives (Figure 1.9) (128).

The RNA structures are capable of performing other regulatory functions as well. The *glmS* riboswitch found in Gram-positives acts in an autocatalytic manner. Upon sensing its ligand, glucosamine, the aptamer domain activates the ribozyme expression platform which cleaves the downstream open reading frame, which encodes glucosamine synthetase.

Cis-encoded sRNAs

Other mechanisms of RNA regulation in bacteria use a small RNA (sRNA) encoded separately from its target mRNA as the regulatory element. One class of these is cis-encoded RNAs, often called antisense RNAs, where the sRNA and target RNA are encoded in the same region from opposite strands. This results in a sRNA with perfect complementarity to its target. This system is common on plasmid, phages, mobile elements and toxin-antitoxin systems, such as the previously described ColE1 origin and Tn10 systems (Figure 1.10).




Figure 1.10: sRNA regulation. Examples of possible outcomes of cis-encoded sRNAs (A). The sRNA can block translation which leads to mRNA degradation, bind to the mRNA and cause cleavage, or stop transcription by binding to the terminator. In trans-encoded (B), the sRNA can bind to the RBS and block translation, recruit nucleases to destabilize the mRNA, or bind to the anti-RBS loop and activate translation (251).

Cis-encoded RNAs are also capable of regulating entire operons. The *gad* genes in *E. coli* are responsible for acid resistance, and two of the regulators are encoded in the *gadXW* operon. The intergenic region contains a promoter on the reverse strand that controls transcription of the *gadY* sRNA. GadY binds to the complementary sequences in the intergenic region with an overlap into the *gadX* coding region. This leads to a processing event that separates the ORFs of the two genes. This stabilizes the *gadX* transcript, which encodes the transcription factor that activates the *gad* acid resistance genes (Figure 1.11) (161, 234). These sRNAs are less well characterized and are much more difficult to identify through standard RNA sequencing unless steps are taken to detect the directionality of reads.




Figure 1.11: GadY. Diagram of the *gadXW* operon. The *gadW* gene also has its own promoter. The GadY sRNA is encoded within the intergenic region of this operon and binds to this region, leading to the cleavage of this operon. The resultant monocistronic *gadX* mRNA is more stable.

Trans-encoded sRNAs

Trans-encoded sRNAs are encoded in different loci than the genes they regulate. They lack perfect complementarity and are considered to function in a roughly analogous

manner to eukaryotic miRNAs (3). In Gram-negative bacteria these sRNAs typically require the RNA chaperon Hfq to mediate binding to their target RNA. There are likely other, as of yet unidentified RNA binding proteins as well.

The majority of known examples of trans-encoded sRNAs regulate their targets in a negative manner. The most common mechanism is for the sRNA to bind to the 5' UTR of a gene and directly block the target transcript's ribosome binding site, which is sufficient to downregulate gene expression (147). However, *in vivo*, the blocking of translation typically leads to the degradation of the target mRNA. Without the ribosomes coating the mRNA during translation, it is vulnerable to degradation by RNases. Additionally, Hfq is capable of binding the endoribonuclease RNase E, the major ribonuclease in *E. coli* and other γ -Proteobacteria, which can then directly degrade the target RNA (47). The secondary ribonuclease RNase III can also be recruited to target mRNAs (160). This ensures that the translation inhibition by sRNAs is irreversible. There are also known cases where the sRNA binds directly to the coding region of the mRNA to destabilize it directly by recruiting an endonuclease. Little is understood about how this mechanism works since the ribosome's helicase activity under other circumstances would be sufficient to remove the sRNA (172). In contrast the positively regulating sRNAs act by breaking the anti-RBS hairpin. While less common, there are still many examples of this form of regulation known (80, 175).

These trans-acting sRNAs are often involved in complex regulatory circuits. A single sRNA is capable of regulating multiple targets, such the *Salmonella* sRNA GvcB, which downregulates seven different ABC transporters (207). The same gene is also capable of

being regulated by multiple sRNAs, often in different manners. In *E. coli*, translation of the stationary phase sigma factor RpoS is blocked by the oxidative stress regulated sRNA OxyS. At the same time, translation is activated by DsrA at low temperatures, and RprA in response to cell surface stress (186). In most cases, the same region of the sRNA interacts with all its targets in a manner analogous to the seed region of eukaryotic sRNAs (257), however there are a few unpublished reports of sRNAs that have multiple target interacting regions.

Other Regulators

There are other regulatory RNAs in bacteria that do not easily fit into these classification schemes. CsrA is an RNA binding protein that binds to conserved GGA motifs in the 5' UTRs of various RNAs to block translation and destabilize them. CsrA has been shown to regulate several different processes including carbon metabolism, biofilm formation, and motility (230). In EHEC, CsrA is able to bind to *LEE1* and *LEE4* and has been shown to regulate virulence in other organisms as well (19, 125). The two sRNAs CsrB and CsrC contain repeated GGA motifs, and are able to act as negative CsrA regulators by sequestering the CsrA protein (9).

The *E. coli* 6S RNA structurally mimics the transcription open complex and binds to the σ^{70} RNA polymerase, preventing it from binding DNA and activating transcription (249). It is highly expressed during stationary phase where it is capable of binding a significant proportion of the σ^{70} holoenzyme, acting as a global repressor of housekeeping genes. However, it is unable to effectively bind to the alternate sigma factor containing RNA

polymerases, including σ^S (235). The 6S RNA also functions as a template for transcription. The resultant 14-20nt product RNA (pRNA) is highly produced during the outgrowth from stationary phase and is involved in the release of 6S from the σ^{70} -RNA polymerase (250). The 6S RNA effectively acts as a switch, allowing the bacterial cell to temporarily shut off a large portion of its transcriptome. Additionally, some sRNAs also encode for peptides or small proteins in addition to their role as RNA mediators (184). There are likely other mechanisms of post-transcriptional regulation that have not yet been discovered.

GLMY AND GLMZ

Glucosamine metabolism

GlmS, glucosamine synthetase, catalyzes the conversion of fructose-6-phosphate to glucosamine-6-phosphate (Figure 1.11). Glucosamine is central to cell metabolism and is absolutely required for bacteria to grow. Barring an exogenous source of glucosamine, GlmS is an essential gene in bacteria. In *E. coli* and other enterobacteria, *glmS* is encoded in the *glmUS* operon. GlmU is a bifunctional enzyme that catalyzes two subsequent steps in glucosamine utilization, the acetylation of glucosamine-1-phosphate to N-acetylglucosamine-1-phosphate, and the transfer of uridine to create UDP-GlcNAC, which serves as the precursor for LPS and cell wall biogenesis (68).




Figure 1.12: Glucosamine pathway. Diagram showing the synthesis of glucosamine from Fru-6-P to UDP-GlcNAc and the enzymes involved. Adapted from Yang, *et al* (262).

Regulation of GlmS

While transcription of *glmU* and *glmS* are permanently linked, the cell does not have equal need for these two enzymes. GlmU is always needed for recycling of the cell wall; however, GlmS is not needed when exogenous glucosamine is available. To solve this problem, the cell regulates *glmS* post-transcriptionally. The *glmUS* operon undergoes an RNase E mediated processing event which separates the *glmU* and *glmS* transcripts. The resultant *glmS* transcript is not only susceptible to polyadenylation and degradation, but its translation is inhibited by a hairpin loop blocking the RBS (98). GlmZ, an Hfq dependent trans-encoded sRNA, binds to *glmS* and relieves this hairpin allowing for its translation, while having no effect on the expression of *glmU* (Figure 1.13) (238).




Figure 1.13: GlmS-GlmZ interaction. GlmS hairpin (left) and GlmS and bound to GlmZ in its translationally active state (right) (238)

GlmY and GlmZ

GlmZ is a 207nt sRNA. There is currently nothing known about its regulation at the transcriptional level, but it is known to be heavily regulated post-transcriptionally. The protein RapZ binds to GlmZ and recruits RNase E to cleave GlmZ towards its 3' end. The resultant 153nt transcript is missing the *glmS* binding region and is unstable (72). Another sRNA, GlmY, has significant sequence homology to GlmZ and nearly identical secondary structure (Figure 1.14). This Hfq-independent sRNA acts as a molecular mimic and binds to RapZ, displacing GlmZ and preventing its processing and degradation (71).




Figure 1.14: GlmY and GlmZ. Secondary structure of GlmY and GlmZ. Arrows indicate known cleavage sites and red lettering indicates the *glmS* binding site (238).

This anti-adaptor RNA GlmY is also regulated post-transcriptionally; it is polyadenylated by the poly(A) polymerase PcnB (100). In bacteria, polyadenylation acts as a degradation signal (146), which results in GlmY having a short half-life. GlmY also undergoes a processing event which does not affect its stability or binding to RapZ. Transcription of *glmY* is controlled by two overlapping promoters, a σ^{70} and a σ^{54} . The σ^{54} promoter is activated by QseF. In a *qseF* mutant *glmY* is not expressed due to the σ^{54} holoenzyme acting as a repressor, suggesting that QseF is the only σ^{54} -dependent activator of *glmY* (184).

This GlmY-GlmZ cascade is also controlled through a glucosamine-6-phosphate feedback mechanism. Upon depletion of GlcN6P, GlmY accumulates in the cell. This is through an unknown mechanism, as transcription of *glmY* is not dependent on levels of GlcN6P (71, 100, 184).

CHAPTER TWO

Overall Objective and Synopsis

Enterohemorrhagic *E. coli* is a major cause of hemorrhagic colitis and hemolytic uremic syndrome (102). The dangers associated with the induction of Shiga toxin due to antibiotic treatment limits the available treatments to palliative care (199). Understanding the regulation of virulence in this organism could lead to better treatments. The key role of cell signaling in the regulation of virulence has made it an interesting target for drug discovery, however, not much is known about the downstream effects of this signaling pathway.

Previous work has shown that the response regulator QseF is required for the expression of *espFu* and thus pedestal formation; however, this regulation was also shown to be indirect and there must be another, unknown factor involved (182). Another investigator subsequently identified QseF as a regulator of the gene encoding the sRNA *glmY* (184). We hypothesize that *glmY* or *glmZ* are the missing element in the regulation of *espFu* and are potentially involved in post-transcriptional regulation of other virulence genes in EHEC. To investigate this, we overexpressed both sRNAs and constructed knockouts of both genes. We showed that *glmY* and *glmZ* are capable of complementing the pedestal formation defect of the *qseF* mutant and are involved in the regulation of *espFu*. We also determined through northern blots that both sRNAs regulate the *LEE4* and *LEE5* operons and determined through site directed mutagenesis that *GlmZ* directly binds the *LEE4* transcript. We also determined that QseB regulates the transcription of *glmY*. Microarray analysis and whole RNA

sequencing of total RNA from these mutants was also performed. We assessed their whole transcriptome and determined that *glmY* and *glmZ* also regulate the expression of curli, which are involved in host cell attachment (113).

In these studies we show that the Qse cell signaling pathway of EHEC regulates the *glmY* and *glmZ* sRNA cascade, which is intimately involved in the post-transcriptional regulation of the LEE and other virulence genes. This level of regulation is likely important for the temporal regulation of the assembly of the type three secretion system and timing of the bacterial infection.

CHAPTER THREE

Methodology

STRAINS, PLASMIDS, AND GROWTH CONDITIONS

All bacteria strains, plasmids, and primers used in this study are listed on Table 1-3. Bacteria were maintained and grown in Luria Bertani (LB) or low glucose Dulbecco's Modified Eagle's Medium (DMEM) at 37°C and 250rpm. When appropriate, media were supplemented, with 50µg/ml streptomycin, 50µg/ml kanamycin, 50µg/ml chloramphenicol, 100µg/ml ampicillin, or 50µg/ml tetracycline. 0.2% arabinose was used to induce pBAD expression vectors.

RECOMBINANT DNA TECHNIQUES

Standard protocols were used for PCR amplification, plasmid purification, restriction enzyme digestion, ligation and transformation (196). Primers were designed using the IDT Oligoanalyzer 3.1 and GenScript Real-time PCR Primer Design. Nonpolar mutants were created using the lambda red recombination system (46). In brief, the plasmid pKD3 was used as a template, primer pairs glmYREDF and glmYREDR for *glmY*, glmZREDF and glmZREDR for *glmZ*, and yhbJREDF and yhbJREDR for *rapZ*, were used to amplify PCR products that were then gel-purified (Qiagen). This was then used as a template for another round of PCR amplification and PCR purified (Qiagen). The strains $\Delta qseC$, wild type and later $\Delta glmY$ were transformed with the temperature sensitive helper plasmid pKD46. Resistant transformants were then streaked onto LB plates and grown overnight (ON) at

30°C. Bacteria on the plate were inoculated into a flask of LB with 25mM arabinose and grown to an OD₆₀₀ 0.5 at 30°C and transformed with the PCR products. The electroporated cells were then recovered in SOC media overnight at room temperature, plated on chloramphenicol supplemented LB plates and incubated overnight at 37°C. Resultant colonies were screened for ampicillin sensitivity and chloramphenicol resistance and checked for proper insertion via PCR. The chloramphenicol cassette was then resolved by electroporating deletion candidates with the resolvase plasmid pCP20, grown at 37°C for 5 hours then screening resulting colonies for sensitivity for both ampicillin and chloramphenicol. Final verification of gene deletion was performed by PCR amplification and sequencing.

Plasmids for mutant complementation, β-galactosidase assays and protein expression were constructed by amplifying the coding regions from the EHEC strain 86-24 using Phusion polymerase (NEB), digesting with appropriate restriction enzymes and ligating with T4-ligase (NEB). The sRNAs *glmY* and *glmZ*, were cloned into pBAD33 using *glmY33F* and *glmY33R*, and *glmZ33F* and *glmz33R*, respectively, to create pCG30 and pCG301. *LEE4* and *LEE5* were cloned into pACYC177 using *lee4F* and *lee4R*, and *lee5F* and *lee5R* to create pCG85 and pCG87. Site-directed mutagenesis was performed using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene). The primers *glmZglmSF* and *glmZglmSR* were used to create *glmZ** in pCG102, *glmZlee4F* and *glmZlee4R* were used to create *glmZ-QC* in pCG77, and *lee4QCF* and *lee4QCR* were used to create *lee4-QC* in pCG89.

The *espJ-espFu* region was amplified using *espJFuF* and *EspJFuR* and cloned into PCR BUNT TOPO (Invitrogen) to create pCG92. Deletion mutants were created using sewing PCR (210) and this plasmid as a template. *EspFuNoUTRF* and *EspFuNoUTRR* created *EspJFu1*, *EspFu2F* and *EspFu2R* created *EspJFu2*, *EspFu3F* and *EspFu3R* created *EspJFu3*, and *EspJF* and *EspJFuR* created *EspFu4*. These PCR products were put into PCR BLUNT TOPO to generate pCG93, pCG94, pCG95, and pCG96, respectively. These including *espJ-Fu* were then subcloned into pACYC177 to generate pCG97, pCG98, pCG99, pCG100, and pCG101.

The *espJ-espFu* constructs were created by first cloning the region from the *espJ* promoter to *espFu* with a FLAG tag added via a primer and inserting it into the Zero Blunt TOPO vector (Invitrogen). The deletion mutants were then generated through sewing PCR. Proper cloning of all plasmids was confirmed by sequencing.

RNA PURIFICATION

Cultures grown overnight aerobically at 37°C in LB were diluted 1:100 into DMEM and grown in triplicate to an OD₆₀₀ of 1.0 or grown for 6 hours at 37°C and 5% CO₂, and then pelleted and suspended in Trizol (Invitrogen). The Ribopure Bacteria isolation kit (Ambion) was then used to extract RNA from these biological replicates according to manufacturer's protocols except for two modifications: Trizol was used instead of RNAwiz, and the cells were not disrupted by vortexing with beads. Samples were DNase I treated to

manufacturer's specifications and the concentration of RNA was determined with a Nanodrop.

NORTHERN BLOT

Bacteria were grown aerobically in low glucose DMEM supplemented with 0.2% arabinose at 37°C to an OD₆₀₀ of 1.0 from a 1:100 dilution of an overnight grown in LB. RNA was extracted and 5µg of each sample was run on a 1% formaldehyde agarose gel and transferred overnight to a Zeta-Probe Membrane (Bio-Rad). RNA probes were created by amplifying a segment of the gene of interest with the T7 promoter and *in vitro* transcribing using the Maxiscript T7 kit (Ambion) with radiolabeled α-UTP. An *espA* probe was created with *espAF* and *espAR*, *sepL* probe with *sepLF* and *sepLR*, *tir* with *tirF* and *tirR*, *eae* with *eaeF* and *eaeR*, *espFu* with *espFuF* and *espFuR*, and *glmS* with *glmSF* and *glmSR*. The oligo probe for the 5S endogenous control was labeled with γ-ATP using T4 polynucleotide kinase (NEB). The membranes were then hybridized ON using Ultrahyb (Ambion) at 68°C for the RNA probes and 37°C for the oligo probes. The membranes were washed and exposed to a phosphorimager screen overnight and then visualized with a STORM scanner (GE Healthcare).

QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION (qRT-PCR)

Quantification of RNA transcription was performed as described previously (246). Extracted RNA was diluted to a concentration of 50ng/µl and mixed with Sybr Green,

validated primers (Table 3), RNase inhibitor and reverse transcriptase (AB). The mix was used in a one-step reaction utilizing an ABI 7500 Fast sequence detection system. Data was normalized to endogenous *rpoA* levels and analyzed using the comparative critical threshold (CT) method. Data was presented as fold changes over wt levels. The error bars represent the standard deviations of the $\Delta\Delta CT$ value. The Student's unpaired t test was used to determine statistical significance, with a p-value of ≤ 0.05 being considered significant.

REPORTER ASSAYS

Transcriptional reporters were constructed using the plasmid pRS551 (213). The *glmY* and *glmZ* promoters were cloned into this plasmid with *glmYtxnF* and *glmYtxnR*, and *glmZtxnF* and *glmZtxnR* to create pCG48 and pCG49. The *espFu* promoter in pCG50 was created previously (155).

The translation fusion vector pCG56 was created by cloning *lacZ* from the *E. coli* strain MG1655 into pBAD24 using the primers *lacZ24F* and *lacZ24R*. The translation reporter vectors were created as follows: pCG59: *glmStslF* and *glmStslR* for GlmS, pCG60: *tirtslF* and *tirtslR*, pCG61: *cesTslF* and *cesTslR*, pCG62: *eaetslF* and *eaetslR*, pCG63: *sepLtslF* and *sepLtslR*, pCG64: *espAtslF* and *espAtslR*, pCG65: *espDtslF* and *espDtslR*, pCG66: *espBtslF* and *espBtslR*, pCG57: *EspJFuF* and *EspJFuR*.

Transcriptional and translational β -galactosidase assays were performed using the same protocol. Bacteria containing the reporter plasmid were grown ON in LB with the appropriate antibiotic and then diluted 1:100 into clear DMEM supplemented with 0.2%

arabinose and grown to an OD₆₀₀ of 0.8 . These were then assayed for β-galactosidase activity using ONPG as previously described (142).

For the experiments with the GlmS::LacZ reporter plasmid, bacteria were grown ON in LB with 0.2% arabinose and assayed as before with the OD₄₂₀ reading normalized using specific activity.

OPERON ANALYSIS BY RTPCR

Wildtype and $\Delta qseF$ strains were grown to an OD₆₀₀ 1.0 in low glucose DMEM and RNA was extracted as described. RNA was converted to cDNA using Superscript II (Invitrogen) and EspFuR (Table 3), according to the manufacturer's specification. cDNA was then amplified by Phusion (NEB) with the primers EspF1 and EspFuR for the larger transcript and EspFu2 and EspFuR for the smaller transcript and run on a agarose gel and visualized with ethidium bromide.

PROTEIN PURIFICATION

The pQE30 plasmid containing QseB was previously constructed (90). This plasmid was transformed into the *E.coli* strain BL-21(DE3) (Invitrogen). Resulting transformants were grown to OD₆₀₀ 0.5 at 37°C in LB, then induced by adding IPTG to a final concentration of 0.5mM and growing for 3 hours at 37°C.

QseF was cloned into pBAD myc/his A using qseFBADF and qseFBADR generating pCG23. This plasmid was then transformed into TOP10 cells (Invitrogen). Resulting

transformants were grown to OD₆₀₀ 0.5 at 37°C in LB, then induced by adding arabinose to a final concentration of 0.2% and growing for 3 hours at 37°C.

Bacteria were lysed in an Emulsiflex in a lysis buffer [50mM sodium phosphate, 300mM NaC, 20mM imidazole, pH 8.0] and nickel columns (Qiagen) were used to purify both proteins from cleared lysates. The nickel beads were washed 5x with lysis buffer and eluted in elution buffer [50mM sodium phosphate, 300mM NaC, 250mM imidazole, pH 8.0]. Purity was verified by Coomassie and Western blot, while the protein concentration was quantified by Nanodrop and the Biorad protein assay.

ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSA)

EMSAs were used to determine binding of purified QseF or QseB to promoter sequences. The assays were performed as previously described (108). Briefly, defined regions of the promoter from 496 bp upstream of the *qseE* translation start site to 4nt in the coding region (Table 3) were amplified by PCR, purified, quantified and end-labeled using radiolabeled γ -ATP (Perkin Elmer) and T4 polynucleotide kinase (NEB) according to manufacturer's instructions. The radiolabeled probes were then repurified to remove unincorporated ATP. EMSAs were performed by adding increasing amounts of purified recombinant protein to 2ng labeled probe in binding buffer [60nM HEPES pH 7.5, 5mM EDTA, 3mM DTT, 300mM KCl, 25mM MgCl₂, 50ng polyIdC, 500 μ g/ml BSA (NEB)] (38). Response regulators were phosphorylated through the addition of lithium acetyl phosphate. The reactions had a final volume of 40 μ l and were incubated for 20 min at room

temperature then loaded on a 6% polyacrylamide gel after addition of a 5% ficol DNA loading buffer. The gel was run at 180V for 6hrs or 50V overnight, dried and exposed on a film.

WESTERN BLOTS

Bacteria were grown overnight in LB and then diluted 1:100 into low glucose DMEM and grown to an OD₆₀₀ of 1.0. The pellets were then lysed under denaturing conditions using Buffer C (100 mM NaH₂PO₄, 10 mM Tris-HCl, 8M urea, pH 6.3) and run on a 12% SDS-PAGE and transferred to a PVDF membrane. The membrane was probed with an α -FLAG antibody (Sigma) or α -RpoA antibody (Santa Cruz Biotechnology) as the endogenous control with a HRP-conjugated secondary antibody that was visualized with ECL (GE Bioscience) and exposed to film.

CELL CULTURE AND FLUORESCENT ACTIN STAINING

HeLa cells were maintained in high glucose DMEM supplemented with 10% FBS and pen-strep glutamine and grown at 37°C and 5% CO₂. Cells were split into a 12 well plate, grown to confluency, washed and given low glucose DMEM supplemented with 10% fetal bovine sera (FBS), and then infected with bacteria grown ON in LB statically at 37°C at a 1:100 dilution. After 3hrs of infection the media was removed and replaced and the infection continued for 3 more hours. The bacteria were then washed, fixed in formaldehyde, permeabilized with 0.2% Triton X-100, strained with FITC-phalloidin, and propidium iodide

as previously described (194). Cells were then visualized by fluorescent microscopy. Statistics were then performed by randomly imaging different fields and counting the first 100 cells while recording the number of bacteria attached to each one. The Student's t-test was used to determine significance.

LIVE-CELL IMAGING

The Lifeact::GFP expressing cell line was created using the Flip-In System (Invitrogen). HeLa cells were transfected with pLacZ::Zeocin using Fugene 6 (Promega) to create FRT sites in the genome. Cells were then selected with 100 μ g/ml zeocin. Resistant foci were grown up and assayed by Southern blot against *lacZ* for single insertions, and then β -galactosidase assays were performed to measure expression of the inserted locus. High expressing single insertions were then transfected with the flippase helper plasmid pOD44 and Lifeact::GFP cloned into the pFRT plasmid. These transfected cells were then selected in 100 μ g/ml hygromycin and resistant foci were visualized under fluorescent microscopy to measure levels of Lifeact::GFP expression. These cells were then maintained in 50 μ g/ml hygromycin. When they are split before infection hygromycin is not added.

EHEC were transformed with the mCherry expressing plasmid pDP151 and grown ON at 37°C statically in LB. The Lifeact::GFP cell's media was replaced with low low glucose DMEM supplemented with 10% FBS and infected with a 1:100 dilution of the ON. The infection was allowed to continue for 2hrs at 37°C and 5% CO₂, then the cells are

washed 3 times with DMEM and visualized by live cell imaging with a Zeiss scope. Images were taken every 2 minutes for 2 hours.

TEMPERATURE SENSITIVE RNASE E

The *rne*^{wt} strain NL3433 and *rne*^{ts} NL3431 strain (8) were transformed with either the *pLEE4* or *pLEE5* plasmids and *pGlmZ*. Both were grown ON in LB at 30°C in the appropriate antibiotics and then grown to an OD₆₀₀ of 1.0 from a 1:100 dilution in LB at 35°C. Once they reached this point, they were shifted to the nonpermissive temperature 43°C for 15 minutes and then RNA was extracted from the samples and used on northern blots as previously indicated.

CONGO RED PLATES

Curli formation was detected by growing bacteria on Congo red plates. 250ml of media was prepared using 2.5g tryptone, 1.25g of yeast extract, and 3.75g agar. Before pouring, Congo red dye was added to a final concentration of 40µg/ml and Coomassie brilliant blue to a final concentration of 20µg/ml. 5µl of each strain of bacteria were spotted onto the plates in triplicate. The plate was incubated at 30°C overnight and then pictures were taken with a color camera.

MICROARRAY GLOBAL ANALYSIS

Microarray global analysis of the transcriptome of wt, $\Delta glmY$, $\Delta glmZ$, and $\Delta rpoS$ strains of EHEC were performed on extracted RNA according to manufacturer's instructions outlined in the Affymetrix Gene Expression Technical Manual. RNA was extracted as previously described and used as a template for reverse transcription to cDNA. This DNA was then fragmented with DNase I, labeled and hybridized to the *E. coli* Genome GeneChip 2.0. The Genechips contain over 10,000 probe sets directed towards 20366 genes from four different strains of *E. coli*: the K-12 laboratory strain MG1655, the O157:H7 EHEC strain EDL933, the O157:H7 EHEC strain Sakai and the uropathogenic strain CFT073.

The results were gathered from scanning the chips and the data was normalized using the MAS5 method. Expression between chips was compared using the using the Affymetrix GeneChip Operating Software v1.4. (93).

RNA SEQUENCING

RNA sequencing was performed twice with different protocols. The first time RNA from wt, $\Delta glmY$, and $\Delta glmZ$ strains were treated with Microb Express (Ambion) to remove rRNA. Samples were then processed with the TruSeq Total RNA sequencing kit (Illumina). In summary, RNA is fragmented, converted to cDNA, ligated to adaptors, amplified, and run on an Illumina sequencing machine using paired-end sequencing.

In the second run, RNA was extracted from wt, $\Delta glmY$, $\Delta glmZ$, and Δhfq grown statically at 37°C. Bacterial mRNA was selectively amplified with the Ovation RNA-Seq System (Nugene) and then processed with the Encore RNA Complete RNA-seq Library

system (Nugene). A paired-end sequencing run was then performed on an Illumina sequencing machine.

The data were analyzed by different methods. Raw reads matched to the EDL933 reference sequence using Bowtie 2 and subsequently compared using the R Bioconductor module DESeq (6). Alternatively the raw data were aligned and analyzed with Rockhopper (131). For visualization purposes, the data were also aligned with Bowtie, sorted and indexed with Samtools, then visualized with BamView in Artemis (31, 119).

Table 3.1: Strains

Strain name	Genotype	Citation
86-24	wild type EHEC O157:H7	(74)
NR02	$\Delta qseF$ 86-24	(183)
MC474	$\Delta qseB$ 86-24	(90)
CG13	$\Delta espFu$ 86-24	This study
CG06	$\Delta glmY$ 86-24	This study
CG07	$\Delta glmZ$ 86-24	This study
N3431	<i>rne-3071</i> ts RNaseE	(8)
N3433	<i>rne</i> ⁺	(8)
MC4100	araD139 Δ (argF-lac)U169 rpsL150 relA1 fblB3501 deoC1 ptsF25 rbsR	(212)

Table 3.2: Plasmids

Plasmid name	Contents	Citation
pRS551	<i>lacZ</i> reporter gene fusion vector	(213)
pBAD24	Cloning vector	(77)
pBAD33	Cloning vector	(77)
pACYC177	Cloning vector	New England Biolabs
Zero Blunt TOPO	Cloning vector	Invitrogen
pFRT/ <i>lacZeo</i>	Plasmid for inserting FRT site	Invitrogen
pOG44	Expresses the Flp recombinase	Invitrogen
pcDNA5/FRT	Cloning region flanked by FRT sites	Invitrogen
pKD3	FRT flanked Cm ^R cassette	(46)
pKD46	λ red recombinase plasmid	(46)
pCP20	ts flippase plasmid	(46)
pCG48	<i>glmY::lacZ</i> in pRS551	This study
pCG49	<i>glmZ::lacZ</i> in pRS551	This study
pCG50	<i>espFu::lacZ</i> in pRS551	(155)
pCG56	LacZ in pBAD24	This study
pCG57	EspFu::LacZ in pCG56	This study
pCG92	EspJ-EspFu::FLAG in TOPO	This study
pCG93	EspJ-EspFu::FLAG deletion 1	This study
pCG94	EspJ-EspFu::FLAG deletion 2	This study
pCG95	EspJ-EspFu::FLAG deletion 3	This study
pCG96	EspJ-EspFu::FLAG deletion 4	This study
pCG30	<i>glmY</i> in pBAD33	This study
pCG31	<i>glmZ</i> in pBAD33	This study
pCG102	<i>glmZ</i> [*] in pBAD33	This study
pCG59	GlmS::LacZ in pCG56	This study
pCG60	Tir::LacZ in pCG56	This study

pCG61	CesT::LacZ in pCG56	This study
pCG62	Eae::LacZ in pCG56	This study
pCG63	SepL::LacZ in pCG56	This study
pCG64	EspA::LacZ in pCG56	This study
pCG65	EspD::LacZ in pCG56	This study
pCG66	EspB::LacZ in pCG56	This study
pCG74	<i>LEE4</i> in pACYC177	This study
pCG89	<i>LEE4QC</i> in pACYC177	This study
pCG77	GlmZQC in pBAD33	This study

Table 3.3: Primers

Oligo name	Sequence
Lambda Red	
glmYREDF	CCTCAAAGCAACGTATAATCAGTACGTTACCAAACATTTTTCTTTATTGGGTGTAGGCTGGAGCTGCTTC
glmYREDR	GAGGGGAAGTTCAGATACAACAAAGCCGGGAATTACCCGGCTTTGTTATGGAATCATATGAATATCCTCCTTAG
glmZREDF	CTCAGGAAGCAAAGAGGATTACAGAATTATCTCATAACAAGTGTTAAGGGTGTAGGCTGGAGCTGCTTC
glmZREDR	GTAGTTCCTTCTACCCGGAGGCAAGCACCTCCGGGACCTTCTGACACATAACATATGAATATCCTCCTTAG
EspFuREDF	GGACATAAGAGACATAACAACACAGGAGGAATGGCTGTTTTTAATAGTGCGTGTAGGCTGGAGCTGCTTC
EspFuREDR	AATAACCGGTAACGTGCAGGTCAGAGCTAATATAGGTAATTATATTATAACATATGAATATCCTCCTTAG
Plasmid	
glmYtxnF	CAT GAATTC CAA CTT CGG GAG CTT TTT TG
glmYtxnR	CAT GGATCC AAG TCG GTG AAT GAG CC
glmZtxnF	CAT GAATTC TGA TAT GTA AGG CAG GTT TAT TAT ATC
glmZtxnR	CAT GGATCC GAG ATG GAA TGA GCA TCT AC
LacZF	CAT CTGCAG ACC ATG ATT ACG GAT TCA C
LacZR	GTA AAGCTT TTA TTT TTG ACA CCA GAC CA
EspFutsIF	CAT GGTACC CCG CAT GAA ACC TTT CTT AGC
EspFutsIR	GTA CTGCAG TGG AAA AAG TGA AGA AAC ATT GTT AA
glmStsIF	CAT GGTACC TTC TGG CCG GGT AAT CC
glmStsIR	GTA CTGCAG CGC ATC AAC AAC GGC CAG
tirtsIF	CAT GGTACC GAT TGT TAT CTA TTT ACA TAA AAT AAA AAG GAG ATA TTT
tirtsIR	GTA CTGCAG CCC TGC ACC GTC GGT TTG
cesTtsIF	CAT GGTACC GGA ATA ACA TTG CTG CAG GAT G
cesTtsIR	GTA GTCGAC AGA ACA CAA TCT GTT TTC ATT AAA TGA AAT AG
eaetsIF	CAT GGTACC AGA TAA AAT CCG ATC TAT TAA TAT AAT TTA TTT CTC ATT C
eaetsIR	GTA CTGCAG AAA CAA TCC TAA ACC AGC ACT AAG C
sepLtsIF	CAT GGTACC GTC TAA GAA TAG AGT AGA AAG GAA GCT G
sepLtsIR	GTA CTGCAG CGT TAA TTG CTG AGA TTC TAA TTC AAA ATC TAA TG
espAtsIF	CAT GGTACC ATT ATT AAT GAT TGG TAA AGT TAT CGA CTA TAA GG
espAtsIR	GTA CTGCAG ATC CTT CGA CAT ATT ACC TAA GTC ATA GAT
espDtsIF	CAT GGTACC GCA ATC TCT ACA ATA TAG AAC TAT TTC AGC
espDtsIR	GTA CTGCAG ACC CGT TTC AGA TTG AGT AAT ACC
espBtsIF	CAT GGTACC TCC GAT TCA GCA CGG GTA AAT AG
espBtsIR	GTA CTGCAG AGC AGA TGC GGC AAC TGC
EspJFuF	CAT GGTACC CAA TAA ATC TCG TCA CTG AGC TCA AT
EspJFuR	CTA CTGCAG TTTATCATCATCTTTATAATCCGAGCGCTTAGATGTATTAATGCC
EspFuNoUTR1R	TTA CCT TAT AAG TAA ATA TGT CAA TAC CTT
EspFuNoUTR2F	AAGGATTGACATAT TTAATAAGGTAA

EspFu2F	AAGGTATTGACATAT GCATGAAACCTTTCTTAGC
EspFu2R	GCT AAG AAA GGT TTC ATG CAT ATG TCA ATA CCT T
EspFu3F	GTTTTTTAATAGTGCTTTGAATTCC TTACTTATAAGGTAA
EspFu3R	TTA CCT TAT AAG TAA GGA ATT CAA AGC ACT ATT AAA AAA C
LEE4F	CAT ggatcc GGG GAA AGC AAA ACG TAA CTG
LEE4R	GTA gacgtc CCG GGA TGA AGC CATCTAAG
glmZQCF	GTTTACGGTGCTTAT GGTCCACTGA G AGATGTCGCTTATGC
glmZQCR	GCA TAA GCG ACA TCT CTC AGT GGA CCA TAA GCA CCG TAA AC
LEE4QCF	GATGCGGTAAAGGCTTTGGAGGACTCTATGGATCATGAGACGAGTCAGTTATTGTACAG
LEE4QCR	CTG TAC AAT AAC TGA CTC GTC TCA TGA TCC ATA GAG TCC TCC AAA GCC TTT ACC GCA TC
EMSA Probe	
glmYPromK12F	GCGGCATTAAGCACCAACCACTAT
glmYPromK12R	ATATCAGAAGTTGGACGGCAGGCA
glmYPromEHECF	CGCCGCATCCGGCATTAAATACAA
glmYPromEHECR	ATATCAGAAGTTGGACGGCAGGCA
glmYPromEPECF	AATCACGACAATGGGTGGTTTGCC
glmYPromEPECR	TGTTACGGAATAAGGCGGTGCCTA
Northern Probe	
EspFuProbeF	CAACCGTCAACCGCAATATTACAG
EspFuProbeR	TAATACGACTCACTATAGGG ATGTTACGCCATACTCCGGgcagg
sepLprobeF	GCCTGGGATATCGCAAAGGTAG
sepLprobeR	TAATACGACTCACTATAGGG AATTCAATCTTAACAACTTAGATTGC
espAprobeF	GGTAATATGTGCGAAGGATGAGG
espAprobeR	TAATACGACTCACTATAGGG CAC GTC TTG AGG AAG TTT GGC
espDprobeF	GGTACTTCTGGTATTACTCAATC
espDprobeR	TAATACGACTCACTATAGGG GAG AGA GAT AGG GAT AGC TTG TG
espBprobeF	CTGCTTACTGATGGTAAGGTTG
espBprobeR	TAATACGACTCACTATAGGG GTT CAT TGC TGC AAA AGA ACC
tirProbeF	GGCGCGTCTGAGATAAC
tirProbeR	TAATACGACTCACTATAGGG CCA CGG CCT CCA GTA AAT AC
cesTprobeF	GGTATTGGATCTATTTCAATTAATG
cesTprobeR	TAATACGACTCACTATAGGG GGA AAC GTA ACG CTA AC
eaeProbeF	CCGGACGTGACCAAAAGC
eaeProbeR	TAATACGACTCACTATAGGG GTA ATA AGA AGT CCA GTG AAC TAC CG
5Sprobe	CTACGGCGTTTCACTTCTGAGTTC
Stable Cell Line	
LifeactF	CAT AAG CTT CAC CAT GGG TGT TG
LifeactR	GTA GCGGCCGC TTA CTT GTA CAG CTC GTC CAT G
qPCR	
rpoA_F	GCGCTCATCTTCTCCGAAT
rpoA_R	CGCGGTCGTGGTTATGTG
ler_F	CGACCAGGTCTGCC
ler_R	GCGCGAACTCATC
espA_F	TCAGAATCGCAGCCTGAAAA
espA_R	CGAAGGATGAGGTGGTTAAGCT
eae_F	GCTGGCCTTGGTTTGATCA
eae_R	GCGGAGATGACTTCAGCACTT
stx2a_F	ACCCACCGGGCAGTT
stx2a_R	GGTCAAAAACGCGCCTGATA
EscF1F	GCGATTCTGTGCCAGAGTTACTT
EscF1R	CCGCAAACTGCAACTCTAACAT
EspF1F	TGGAATTAGTAACGCTGCTTCTACA
EspF1R	CCCCCGCAGAGCTCACT

CHAPTER FOUR

Post-transcriptional Control of Microbial-Induced Rearrangement of Host Cell Actin

INTRODUCTION

Exploitation of the host cytoskeleton by bacterial pathogens is an essential feature of bacterial-host associations. Actin remodeling promotes bacterial invasion of non-phagocytic cells, survival within cells, cell-to-cell spread and locomotion, and colonization at the interface of the host epithelium (30, 65, 88). Although there is vigorous investigation of the cell biology underlying these bacterially-mediated cytoskeleton modifications, knowledge of the plasticity and dynamics of the bacterial signaling networks that regulate expression of genes necessary for these phenotypes is lacking. Enterohemorrhagic *Escherichia coli* (EHEC) O157:H7 is a major food-borne pathogen and causative agent of hemorrhagic colitis and hemolytic uremic syndrome (HUS). The mortality associated with EHEC infections stems from the production and release of a potent Shiga toxin by these bacteria. Shiga toxin induces cell death in endothelial cells, primarily in the urinary tract, causing HUS (102). EHEC attaches to epithelial cells of the intestinal lining and forms an attaching and effacing (AE) lesion. These lesions are characterized by the effacement of microvilli and the formation of a pedestal-like structure beneath each individual bacterium (220). To induce pedestal formation on epithelial cells, EHEC employs a type three secretion system (T3SS), a needle-like structure that translocates bacterial effectors directly within host cells. This T3SS together with several other genes necessary for AE lesion formation are encoded within a chromosomal pathogenicity island named the locus of enterocyte effacement (LEE) (95,

133). The LEE region contains five major operons: *LEE1-5* (55, 58, 136), which encode the components of the T3SS (95), an adhesin (intimin) (96) and its receptor Tir, which is itself translocated through the T3SS to the host cell, where upon its insertion in the cell membrane it serves as a receptor for the bacterial adhesin intimin (109) and other effector proteins (56, 101, 110, 134, 236). The LEE encoded T3SS also translocates effector proteins encoded outside of the LEE region, including EspFu/TccP, which is important for efficient AE lesion formation (28, 49, 66, 231).

Expression of the LEE and *espFu* genes is governed through complex multi-layered signaling cascades in response to many environmental cues including human hormones (epinephrine [Epi] and norepinephrine [NE]), bacterial small signaling molecules (autoinducer-3 [AI-3], indole, acyl homoserine lactones), carbon and nitrogen sources, and stress responses among others. This regulation occurs both at the transcriptional and post-transcriptional levels (19, 20, 91, 106, 107, 123, 135, 156, 165, 205, 218). In bacteria, there are many different mechanisms of post-transcriptional regulation of genes (221). One of the more abundant classes is *trans*-acting small RNAs (sRNAs). These sRNAs require the RNA chaperone Hfq and act by directly binding to mRNAs at the ribosome binding site (RBS) to repress translation, cause direct degradation of the mRNA by recruitment of nucleases, or activate translation by relieving a hairpin that blocks the RBS. While genes of the LEE are known to be post-transcriptionally regulated, no sRNAs responsible for this have been identified to date.

The AI-3/epinephrine (Epi)/norepinephrine (NE) inter-kingdom signaling cascade activates expression of virulence genes in EHEC (36, 217, 218, 245). The host hormones Epi/NE are specifically sensed by two membrane-bound histidine sensor kinases (HKs): QseC and QseE, which are the first bacterial adrenergic receptors identified (35, 182). QseE is downstream of QseC in this signaling cascade, given that transcription of *qseE* is activated through QseC (183). In addition to sensing these host hormones, QseC also senses the bacterial signal AI-3 (36). QseE, however, does not sense AI-3, thereby discriminating between host and bacterial-derived signals (182). Upon sensing their respective signals, QseC and QseE autophosphorylate and activate the virulence gene expression and pathogenesis *in vitro* and *in vivo* in EHEC (36, 180, 182). QseC transfers its phosphate to three response regulators (RR): QseB, QseF and KdpE, which upon phosphorylation are activated and function as transcription factors (90). QseE only transfers its phosphate to QseF (261). The concerted action of these RRs activates the EHEC virulence repertoire, including the LEE and *espFu* genes (Figure 4.1A). The QseF RR is necessary for the expression of EspFu (183), and it is known to regulate the sRNA GlmY, encoded right upstream from the *qseEGFglnB* operon (Figure 4.1B) (184). This sRNA is known to act as a molecular mimic (71), stabilizing another sRNA (GlmZ), which directly binds to the mRNA of the gene encoding for glucosamine synthetase (*glmS*), and activates its translation by breaking a hairpin loop and revealing the RBS (238).

Here we show that both the QseB and QseF RRs directly activate expression of *glmY*. GlmY and GlmZ coordinate LEE and EspFu expression post-transcriptionally through two

different mechanisms. We used a combination of genetic, biochemical and cell biology approaches to show that GlmY and GlmZ post-transcriptional regulation of the LEE and EspFu ensures the correct timing and dynamics of AE lesion formation by EHEC on epithelial cells. We propose that sRNA-mediated post-transcriptional regulation is responsible for the plasticity and dynamic rewiring of expression of different components of bacterial complex machineries that allow successful interactions with mammalian cells.

RESULTS

Transcriptional Regulation of *glmY* and *glmZ*

The QseC/QseE signaling system controls a plethora of virulence genes in EHEC that have to be coordinately expressed to ensure optimal AE lesion formation on epithelial cells, leading to host infection (37, 90, 154, 180). AE lesion formation is a dynamic process that requires plasticity and rapid adaptation of bacterial gene expression. Coupling transcriptional and post-transcriptional regulation within a signaling transduction cascade in the bacterial cell is key to ensuring fine tuning, and rapid adaptation of gene expression towards regulation of complex processes, such as AE lesion formation. Upstream of the *qseEGFglnB* operon is *glmY* (Figure 4.1B). The *glmY* gene is known to have two overlapping promoters, one that is driven by a σ^{70} -RNA polymerase (the homeostatic form of this enzyme), and another that is driven by a σ^{54} -RNA polymerase (Figures 4.1B and C). Transcription of *glmY* is known to be regulated by the σ^{54} -dependent transcriptional activator QseF (184). Additionally, a sequence matching the known consensus sequence of QseB (38), another RR

involved in inter-kingdom signaling was identified *in silico* in this promoter region (Figure 4.1C).

Transcriptional β -galactosidase reporters of the promoters of both *glmY* and *glmZ* were constructed. As previously reported, in the *qseF* mutant *glmY* expression is starkly decreased and almost ablated, and the *qseB* mutant, while still expressing *glmY*, expressed significantly less than wild-type (wt) (Figure 4.1D). This result was confirmed by northern blot against the GlmY RNA (Figure 4.1E). Neither RR had any effect on *glmZ* expression (Figure 4.1F). The almost complete ablation of expression of *glmY* in Δ *qseF* is due to the σ^{54} -RNA polymerase acting as a repressor in the absence of QseF (184). The σ^{54} -RNA polymerase cannot promote the formation of the DNA open complex to initiate transcription by itself; it requires a σ^{54} RR, such as QseF, for this process (78). Because the σ^{54} promoter overlaps with the σ^{70} , in the absence of QseF the σ^{54} -RNA polymerase occupies the σ^{54} binding site and prevents access to the σ^{70} -promoter by the σ^{70} -RNA polymerase (184).

Electrophoretic mobility shift assays (EMSAs) demonstrated that both QseB and QseF directly bind to the *glmY* regulatory region (Figure 4.1G). Interestingly, while the QseB consensus sequence within the *glmY* regulatory region differs slightly between the EHEC strain 86-24, and the K12 strain MG1655 and the enteropathogenic *E. coli* (EPEC) E2348/69 strains, all are capable of binding to QseB (Figure 4.2).




Figure 4.1: Figure 1. QseF and QseB regulation of *glmY*. (A) Schematic representation of the QseC and QseE transduction signaling systems showing the signals the kinases respond to and the response regulators they are capable of phosphorylating. (B) Schematic representation of *glmY* and *qseEGFglnB* operon depicting the location of σ^{54} and σ^{70} promoters. (C) Diagram showing the layout of the *glmY* regulatory region. QseF binding sites are depicted in red, QseB binding sites are depicted in blue, σ^{54} and σ^{70} promoters are depicted in magenta and yellow, respectively. (D) β -galactosidase assay of the *glmY::lacZ* transcriptional fusion in wt, $\Delta qseB$ and $\Delta qseF$ strains. (E) β -galactosidase assay of the *glmZ::lacZ* transcriptional fusion in wt, $\Delta qseB$ and $\Delta qseF$ strains. (F) Northern blot with a *glmY* probe of RNAs from wt, $\Delta qseB$ and $\Delta qseF$. Northern blot of a 5S rRNA probe of the same RNAs, loading control. (G) EMSAs of the *glmY* promoter with increasing amounts of QseF or QseB protein in the presence of acetyl phosphate. EMSAs of the *kan* promoter with QseF and QseB, negative control.



Figure 4.2: QseB binding sites in EHEC, EPEC and K-12. (A) Alignment of the *glmY* regulatory region between depicting the QseB binding site of EHEC 86-24 and K-12 MG1655. (B) EMSAs of the *glmY* regulatory region from EHEC 86-24, K-12 MG155, and EPEC E2348/69 with the QseB protein.

Regulation of EspFu by QseF

Because the QseF RR controls AE lesion formation by indirectly promoting expression of the EspFu T3SS effector (183), next we investigated whether GlmY and/or GlmZ also played a role in EspFu expression. EspFu interacts with another effector, Tir, through IRTKS and acts as an Nck mimic to recruit N-WASP and Arp2/3 to the site of bacterial attachment causing the formation of the characteristic actin-rich pedestal (Figure 4.3A) (28, 66, 239). The expression of this effector is dependent on QseF, with the *qseF*

mutant having the same phenotype as $\Delta espFu$, which is the almost complete lack of AE lesion formation on HeLa cells (Figure 4.3A and 4.3B) (28, 66, 183).

Since the regulation of *espFu* by QseF is known to be indirect (183), we tested the ability of its known target, GlmY, as well as its downstream target GlmZ, to complement a *qseF* mutant. The *glmY* and *glmZ* genes were cloned under the control of an inducible promoter and transformed into the $\Delta qseF$ strain. These strains were then used to infect HeLa cells to perform the fluorescein actin staining (FAS) test to visualize AE lesions. In the FAS assay the HeLa cytoskeleton was stained in green with fluorescein isothiocyanate (FITC)-labeled phalloidin, and the bacteria and nuclei were stained in red with propidium iodide, pedestals were visualized as brilliant patches of green underneath a red bacterium. Both sRNAs were able to rescue AE lesion formation in the *qseF* mutant, indicating that these sRNAs are the intermediaries between QseF and *espFu*. (Figure 4.3B).

Since sRNAs act post-transcriptionally, we investigated the *espFu* mRNA levels using northern blots. *EspFu* is encoded outside of the LEE within a prophage. Upstream of the *espFu* gene is the *espJ* gene that encodes another T3SS effector (Fig. 4.3E) (130). In the WT, there is a major band the size of the predicted *espFu* transcript (1100bp), as well as a much fainter upper band of 2100 nucleotides in length. In the *qseF* mutant, the lower band is still present, however the upper band is much more pronounced. This upper band corresponds to the expected size of an *espJ-espFu* transcript (Figures 4.3C and 4.3E). There are 320bp between these two genes, and previous work suggested they were not co-transcribed. However, since only RNA from wt bacteria was used in those experiments, it




Figure 4.3: . Post-transcriptional regulation of EspFu. (A) Schematic representation of AE lesion formation. (B) FACS of HeLa cells infected by wt, $\Delta qseF$, and $\Delta qseF$ complemented with p*glmY* or p*glmZ*. (C) Northern blot using an *espFu* probe on RNA from wt, $\Delta qseF$, and $\Delta espFu$, Northern with a 5S rRNA probe with the same RNAs, loading control. (D) RT-PCR of cDNA from wt and $\Delta qseF$ using primer sets to the entire *espJ-espFu* region or just *espFu*. (E) Schematic representation of the *espJ-espFu* region and the 2100 *espJ-espFu* and the 1100 *espFu* transcripts. (F) β -galactosidase assay of the *espFu::lacZ* transcriptional fusion in wt and $\Delta qseF$. (G) β -galactosidase assay of a *EspFu::LacZ* translation reporter plasmid in wt, $\Delta qseF$, and $\Delta qseF$ complemented. (H) Diagram of the *espJ-espFu* WT and deletion constructs. (I) Western blots of wt EHEC expressing *espJ-espFu* WT and deletion Flag-tagged constructs probed with an anti-flag antibody.

is possible that the less abundant larger transcript was not detected (183). To confirm whether this larger transcript is *espJ-espFu*, RT-PCR was performed using primers spanning this region. While a very faint band corresponding to *espJ-espFu* (2100bp) transcript is observed in WT EHEC, it is much more pronounced in the *qseF* mutant (Figure 4.3D). Therefore the lack of EspFu expression in a *qseF* mutant is not due to the absence of its transcript, but the lack of a processing event of the *espJ-espFu* transcript necessary for EspFu expression.

Transcriptional and translational reporters of *espFu* were constructed. As expected, the $\Delta qseF$ had no defect in *espFu* transcription (Figure 4.3F); however it is required for the translation of EspFu (Figure 4.3G). To determine the regions of the *espJ-espFu* required for this regulation, various deletions in the intergenic region between these genes were constructed. These deletions were cloned into a vector with a FLAG-tag on the C-terminus of *espFu*. Four deletion mutants were constructed using the previously identified 5' untranslated region (UTR) of the *espFu* transcript as a reference point (183): p1 that lacks the entire intergenic region, p2 that lacks the *espJ* 3' UTR, p3 that lacks the *espFu* 5' UTR, and p4 that does not have the *espJ* gene but still has the intergenic region (Figure 4.3H). Western blots using anti-flag antiserum were performed on whole cell lysates of EHEC expressing the WT *espJ-espFu*-Flag plasmid and each of these four deletions constructs. The p2 and p4 constructs expressed similar levels of EspFu::Flag to the WT plasmid, while p1 expressed more protein, and p3 did not express EspFu (Figure 4.3I). These data indicate that the 3' UTR of *espJ* acts negatively on the translation of *espFu*, and this QseF/GlmY/GlmZ-

mediated processing event is required for the translation of *espFu* since the resulting transcript lacks the 3' UTR of *espJ*. Additionally, the presence of EspFu::FLAG from the p4 plasmid indicates that in addition to being co-transcribed with *espJ*, *espFu* also has its own promoter (Figure 4.3I).

The role of GlmY and GlmZ in pedestal formation

Given that EspFu is involved in pedestal formation, we further investigated the role of GlmY and GlmZ in AE lesion formation by constructing $\Delta glmY$ and $\Delta glmZ$ strains, and performing FAS assays with these mutants. Since they were both capable of rescuing the *qseF* phenotype, we expected that both mutants would present a decreased ability to form pedestals similarly to the $\Delta qseF$ and $\Delta espFu$ strains. Surprisingly, both sRNAs mutants attached to and formed pedestals on HeLa cells at levels far higher than the wt strain. Both the *glmY* and *glmZ* plasmids were capable of complementing the *glmY* mutant, which is an expected result (Figures 4.4A and 4.4B). The GlmY sRNA is known to stabilize the GlmZ sRNA (238), and GlmZ in a Hfq-dependent manner exposes the RBS of the *glmS* mRNA to promote its translation (238). Thus far, the only known target for GlmY and Z regulation in *E. coli* was *glmS*. The “effector” sRNA that base-pairs with the *glmS* mRNA is GlmZ, and thus the effect of GlmY in *glmS* is indirect and solely attributed to its stabilization of GlmZ (238). However, the *glmY* plasmid was also capable of complementing the $\Delta glmZ$, which suggests that GlmY may have additional functions besides preventing the degradation of GlmZ (Figures 4.4A and 4.4B). Because in addition to *espFu*, AE lesion formation also

requires the expression of the LEE genes, we assessed LEE regulation by these sRNAs. Expression of the *stx2a* gene encoding Shiga toxin and of *ler* (*LEE1* operon), the master regulator of the LEE, was unchanged, but expression of the *LEE4* (*espA*) and *LEE5* (*eae*) operons was decreased in the wt strain expressing GlmY or GlmZ on a plasmid (Figures 4.4C and 4.4D), suggesting that these sRNAs decrease *LEE4* and 5 expression post-




Figure 4.4: GlmY and GlmZ regulation of AE lesion formation and the LEE genes. (A) FAS of HeLa cells infected with wt, $\Delta espFu$, $\Delta glmY$, $\Delta glmZ$ complemented with p*glmY* or p*glmZ*, $\Delta glmZ$, and $\Delta glmZ$ complemented with p*glmY* or p*glmZ*. (B) Quantification of the FAS experiment measuring the average number of bacteria attached per cell. (C) qPCR of *ler*, *espA*, *eae*, and *stx2a* using RNA extracted from wt, wt overexpressing p*glmY* and wt overexpressing p*glmZ*. (D) Schematic representation of the LEE region depicting the *LEE1-5* and *grlRA* operons. Ler is encoded by the first gene in the *LEE1* operon and is the transcriptional activator of all the LEE genes.

transcriptionally. These data offer an explanation for why deletion of the genes encoding these sRNAs increases AE lesion formation. In the absence of these sRNAs, the transcripts of *LEE4* and *LEE5* operons (containing many genes essential for pedestal formation) would be stabilized, increasing pedestal formation.

The role of GlmY and GlmZ in regulation of AE lesion formation by promoting EspFu translation and destabilizing LEE transcripts (Figures 4.3 and 4.4), seems to be initially confounding. However, AE lesion formation is a dynamic process, where pedestals are constantly being formed and unformed during infection, and the precise modulation of the levels of LEE and EspFu expression are important for the efficiency of this phenotype. To better understand the dynamics of pedestal formation responsible for the phenotype of the *glmY* and *glmZ* EHEC knockouts, we wanted to visualize the cells in real time. The F-actin binding peptide Lifeact (187) proved to be the most effective at visualizing the pedestals formed by EHEC. For ease of experimentation, a cell line stably expressing Lifeact::GFP was created. Bacteria were visualized by expression of mCherry (Figure 4.5A-C). The $\Delta glmY$ and $\Delta glmZ$ strains attached to and formed pedestals much more efficiently and faster than the WT strain, suggesting that these sRNAs regulate the proper timing and amount of AE lesion formation on epithelial cells.

GlmY and Z are known to promote translation of *glmS* that encodes the glucosamine synthase enzyme in the *E. coli* K-12 strain MC4100. GlmS is necessary for the synthesis of N-acetylglucosamine-6-P, which is used for cell wall biosynthesis (Figure 4.6A) (238). A




Figure 4.5: GlmY and GlmZ regulation of AE lesion timing and dynamics. (A) Time lapse microscopy of Lifeact::GFP expressing HeLa cells being infected with mCherry expressing wt EHEC. White arrows show clusters of EHEC AE lesions. (B) Time lapse microscopy of Lifeact::GFP expressing HeLa cells being infected with mCherry expressing $\Delta glmY$ EHEC. (C) Time lapse microscopy of Lifeact::GFP expressing HeLa cells being infected with mCherry expressing $\Delta glmZ$ EHEC.

glmS mutant is lethal because it is defective for cell wall biosynthesis. However, addition of 1% N-acetyl-glucosamine (GlcNAC) to the media allows the survival of a *glmS* mutant, because the GlcNAC sugar needed for cell wall synthesis is being provided exogenously (242). To rule out the possibility that the AE lesion phenotype governed by GlmY and GlmZ is due to defects in cell wall synthesis in these sRNAs mutants because of the decreased expression of GlmS, FAS assays were repeated in media containing 1% GlcNAC. The AE lesion phenotypes of the *glmY* and *glmZ* mutants, which form pedestals at

a much higher rate than the wild type, was the same both in the absence or presence of GlcNAC (Figure 4.6B and C). Additionally, point mutations in *glmZ* that abolish




Figure 4.6: GlcNac and GlmS are not involved in the GlmY/GlmZ-dependent AE lesion phenotype. (A) Scheme depicting the mechanism of GlmZ regulation of *glmS* translation. (B) FAS of HeLa cells infected with *wt*, Δ *glmY*, Δ *glmZ* in the absence and presents of 1% GlcNAC. (C) Quantification of the FAS of HeLa cells infected with *wt*, Δ *glmY*, Δ *glmZ* in the absence and presence of 1% GlcNAC depicting the average number of bacteria attached per cell. (D) Sequence and structure of the GlmZ sRNA . Arrows depict the site-directed mutations created to disrupt GlmZ/*glmS* pairing. This mutant is named GlmZ*. (E) FAS of HeLa cells infected with *wt*, Δ *glmZ*, Δ *glmZ* complemented with pGlmZ and Δ *glmZ* pGlmZ*, a mutant of GlmZ that is incapable of binding to *glmS*. (F) Quantification of the FAS of HeLa cells infected with *wt*, Δ *glmZ*, Δ *glmZ* complemented with pGlmZ and Δ *glmZ* pGlmZ*, a mutant of GlmZ that is incapable of binding to *glmS* depicting the average number of bacteria attached per cell.

the regulation of *glmS* by GlmZ were created as previously reported, and the mutant GlmZ was named GlmZ* (Figure 4.6D) (238). This GlmZ* was still capable of complementing

pedestal formation in the *glmZ* mutant, indicating that the pedestal formation phenotype is not mediated through downstream effects of diminished GlmS expression or issues with cell wall biosynthesis (Figure 4.6E and F). To further assess the levels of GlmS expression promoted by GlmY and Z in EHEC, northern blots of *glmS* were performed on RNA from wt EHEC, and wt EHEC expressing GlmY, GlmZ and GlmZ* on a plasmid. It has been previously reported that in *E. coli* K-12 strain MC4100, expression of the *glmZ* mRNA is increased by expression of these sRNAs on plasmids due to the more efficient translation of *glmS* (238). In EHEC, however, expression of both of these sRNAs on plasmids, did not affect the levels of the *glmS* transcript under the conditions we assayed (Figure 4.7A). We also created a translational reporter of GlmS. Previous studies indicate that overexpression




Figure 4.7: GlmY and glmZ regulation of *glmS* in EHEC and K-12 MC4100. (A) Northern blot against *glmS* using RNA from with wt, Δ *glmZ*, Δ *glmZ* pGlmZ and Δ *glmZ* pGlmZ*. (B) β -galactosidase assay of the pGlmS::LacZ translation reporter in wt EHEC, wt overexpressing *glmY*, and wt overexpressing *glmZ*. (C) β -galactosidase assay of the pGlmS::Lac translation reporter in MC4100, MC4100 overexpressing *glmY*, and MC4100 overexpressing *glmZ*.

of either *glmY* or *glmZ* should lead to an increase in β -galactosidase activity with this reporter construct. However, in EHEC, overexpressing *glmY* or *glmZ* did not change GlmS::LacZ expression (Figure 4.7B). This same reporter plasmid was then assayed in MC4100, the *E. coli* K12 strain used in previous study on *glmS* (184, 238), and it behaved as previously reported (Figure 4.7C). Since the sequences of both *glmS* and *glmZ* that interact are invariant between these two strains, it is likely there is another level of regulation that is masking the regulation of *glmS* by GlmZ in EHEC 86-24 that is not present in MC4100.

Post transcriptional regulation of *LEE5* and *LEE4* by GlmY and GlmZ

The *LEE5* operon in EHEC consists of three genes that encode the translocated intimin receptor (*tir*), its chaperone (*cesT*), and the bacterial adhesin intimin that Tir interacts with (*eae*) (Figures 4.5A and 4.2A) (55, 58). While this operon is transcribed by a single promoter upstream of *tir* (1, 54, 216), there is a processing event that results in the separation of *cesT-eae* from *tir* (Figures 4.8A-D). Inasmuch as GlmY and GlmZ over-expression decreased the levels of the *eae* transcript (Figure 4.8A), we investigated the mRNA levels of each gene in this operon by northern blot (Figure 4.8B). Over-expression of both sRNAs decreased the levels of the *cesT-eae* transcript (3300bp) (Figures 4.8C and D), while the *tir* transcript was largely unaffected (1600bp) (Figure 5B). The levels of transcription of the entire *LEE5* operon (4900bp) were also decreased by these sRNAs (Figures 4.8B-D). Since the first gene of this operon is unaffected, GlmY and GlmZ must be acting post-transcriptionally. One of the primary ways sRNAs affect gene stability is by blocking




Figure 4.8: GlmY and GlmZ regulation of the *LEE5* operon. (A) Schematic depiction of the *LEE5* operon and its transcripts. (B) Northern blots using a probe against *tir* using RNA from wt, bacteria overexpressing *glmY*, and bacteria overexpressing *glmZ* with the 5S rRNA serving as a loading control. (C) Northern blots using a probe against *cesT* using RNA from wt, bacteria overexpressing *glmY*, and bacteria overexpressing *glmZ* with the 5S rRNA serving as a loading control. (D) Northern blots using a probe against *eae* using RNA from wt, bacteria overexpressing *glmY*, and bacteria overexpressing *glmZ* with the 5S rRNA serving as a loading control. (E) β -galactosidase assays of *Tir::LacZ* translational fusion in wt, wt/p*GlmY*, wt/p*GlmZ*, Δ *glmY*, and Δ *glmZ*. (F) β -galactosidase assays of *Eae::LacZ* translational fusion in wt, wt/p*GlmY*, wt/p*GlmZ*, Δ *glmY*, and Δ *glmZ*. (G) β -galactosidase assays of *CesT::LacZ* translational fusion in wt, wt/p*GlmY*, wt/p*GlmZ*, Δ *glmY*, and Δ *glmZ*.

translation by binding to the RBS (251). An mRNA being translated is largely protected from nuclease by the ribosomes, so blocking translation can lead to the degradation of the transcript. To test this possibility, translational LacZ reporters were constructed of all three genes of *LEE*, and β -galactosidase assays were performed (Figure 4.8E-G). Neither the knockouts of *glmY* and *glmZ* nor did their overexpression have any effect on the translation

of any of the three reporter proteins, suggesting that they are not acting through this mechanism.

The *LEE4* operon encodes the SepL regulator of effector translocation into host cells, the EspA protein that forms a filament that creates a sheath around the T3SS needle, the EspBD proteins that create a pore through the eukaryotic cell membrane, a chaperone CesD2, the EscF structural protein of the needle, an uncharacterized protein Orf29, and the effector EspF (41, 49, 58, 116, 136, 202). The first gene of this operon (*sepL*) is processed from this operon in a RNase E dependent manner (123), and there is a terminator in the *cesD2* gene that leads to lower expression of the last three genes (136) (Figure 4.9A). Similarly to our studies concerning the post-transcriptional regulation of *LEE5* (Figure 4.8), northern blots were performed for *LEE4* genes in wt, wt overexpressing *glmY* or *glmZ*, and the *glmY* and *glmZ* mutants (Figure 4.9B). Similarly to *LEE5*, over-expression of both sRNAs leads to lower levels of the *espA-cesD2* transcript, while the *sepL* transcript was mostly unaffected. The level of the *espA-cesD2* transcript was noticeably higher in the sRNAs mutants (Figure 4.9B). The transcript of the last three genes of the *LEE4* operon could not be detected by northern blot, because of their much lower expression due to the transcription terminator in *cesD2*, however qPCR demonstrated that they were also down regulated by overexpression of *glmY* and *glmZ* (Figure 4.9C). Translational fusions of SepL, EspA, EspD, and EspB were constructed and assayed, and again expression of these reporters were unaffected in the $\Delta glmY$ or $\Delta glmZ$ strains, and by over-expressing the two sRNAs (Figure 4.9D-G). In a

similar scenario to the post-transcriptional regulation of *LEE5* (Figure 4.8), GlmY and GlmZ are not destabilizing the *LEE4* transcripts by blocking translation (Figure 4.9).

Some sRNAs bind directly to the coding region of their mRNA target transcript, and cause its degradation through the recruitment of a ribonuclease (251). The IntaRNA software (25) was used to predict potential binding sites of GlmY and GlmZ to the coding regions of *LEE5* and *LEE4*, then point mutants that would affect binding were created for each prediction. These mutants were then assayed by their ability to complement the *glmY* and *glmZ* mutants in FAS test and qRT-PCR of target genes. While we have been unable to find any direct binding site (either *in silico* or empirically) of GlmZ or GlmY to the *cesT-eae* transcript, one prediction of GlmZ binding to the *orf29* region of the *LEE4* operon was promising (Figures 4.9H and I). We generated a GlmZ mutant changing two C residues to G residues to prevent base pairing with the *LEE4* operon (Figure 4.9I). This GlmZ mutant, named GlmZ-CG, was unable to complement the pedestal formation of the *glmZ* knockout (Figure 4.9K), nor did it complement expression of the *LEE4* gene *espA* (Figure 4.9J). To confirm this result, the corresponding compensatory mutations were made in a plasmid containing the entire *LEE4* operon, so that in the presence of both GlmZ-CG and *LEE4*-GC the interaction would be restored (Figure 4.9J). This was tested using qPCR against *espA*. The *glmZ*-GC plasmid is unable to complement the increased levels of *espA* in $\Delta glmZ$; however *LEE4*-GC restores this regulation (Figure 4.9J). This indicates that GlmZ is interacting with *LEE4* at the predicted site, and that this interaction is responsible for the regulation of *LEE4* by GlmZ.

A LEE4 operon










Figure 4.9: GlmY and GlmZ regulation of the *LEE4* operon. (A) Schematic depiction of the *LEE4* operon and its transcripts. (B) Northern blots using probes against *sepL* and *espA* using RNA from wt, wt/pGlmY, wt/pGlmZ, Δ *glmY*, and Δ *glmZ*, with the 5S rRNA serving as a loading control. (C) qPCR of *escF* and *espF* using cDNA from wt, wt over-expressing *glmY* or *glmZ*. (D) β -galactosidase assays of SepL::LacZ translational fusion in wt, wt/pGlmY, wt/pGlmZ, Δ *glmY*, and Δ *glmZ*. (E) β -galactosidase assays of EspA::LacZ translational fusion in wt, wt/pGlmY, wt/pGlmZ, Δ *glmY*, and Δ *glmZ*. (F) β -galactosidase assays of EspD::LacZ translational fusion in wt, wt/pGlmY, wt/pGlmZ, Δ *glmY*, and Δ *glmZ*. (G) β -galactosidase assays of EspB::LacZ translational fusion in wt, wt/pGlmY, wt/pGlmZ, Δ *glmY*, and Δ *glmZ*. (H) Sequence and secondary structure of the GlmZ sRNA depicting the regions that interact with the *glmS* and *LEE4* mRNAs. (I) Schematics showing the predicted interaction between GlmZ and *LEE4*, the point mutants made in GlmZ to abolish binding and the compensatory mutations made in *LEE4*. (J) qRT-PCR of *espA* with cDNA from wt p*LEE4*, Δ *glmZ* p*LEE4*, Δ *glmZ* pGlmZ p*LEE4*, Δ *glmZ* pGlmZ-CG p*LEE4*, and Δ *glmZ* pGlmZ-CG p*LEE4*-GC. (K) FAS of HeLa cells infected with wt, Δ *glmZ*, Δ *glmZ* pGlmZ, and Δ *glmZ* pGlmZ-CG.

Since GlmY and GlmZ mediated regulation of *LEE4* and *LEE5* does not act through repression of translation, it is likely that they recruit a nuclease that then degrades the transcripts. The major *E. coli* ribonuclease RNase E is known to be recruited to many sRNA-mRNA complexes, and it has been previously shown to mediate processing of the *LEE4* transcript (123). While *rne* is an essential gene, there is a well characterized *E. coli* K-12 temperature sensitive mutant (8) that we used to test whether RNase E is involved in the GlmZ-dependent post-transcriptional regulation of *LEE4* and *LEE5*. Since this strain is a K12 strain, plasmids containing the entire *LEE4* or *LEE5* operons along with the *glmZ* over-expression plasmid were transformed into the *rne*^{wt} (wild-type) and *rne*^{ts} (temperature sensitive mutant) strains. The bacteria were heat-shocked for 15 minutes before RNA was extracted. This was sufficient to stop the RNase E mediated processing of *sepL* from *espA*

as previously reported (123), however, it had no effect on the GlmZ downregulation of the *espA-cesD2* transcript. (Figure 4.10). The processing of *tir* from *cesT-eae* is also RNase E dependent, but GlmZ is able to function without the presence of RNase E (Figure 4.10). These data show that in both cases, *LEE4* and *LEE5* are processed by RNase E, however GlmZ does not act by recruiting this nuclease. Another potential nuclease known to be recruited by sRNAs is RNaseIII. While the *rnc* gene is not essential, the knockout in 86-24 proved to be extremely sick and has a severe defect in growth, so we were unable to assay this mutant.




Figure 4.10: GlmY and GlmZ regulation of the *LEE4* operon. Northern blots against *sepL*, *espA*, *tir*, and *eae* with the 5S rRNA serving as a loading control on RNA from heat shocked *rne^{wt}*, *rne^{wt}* overexpressing *glmZ*, *rne^{ts}*, and *rne^{ts}* overexpressing *glmZ*

DISCUSSION

By asking the question of how an extracellular bacterial pathogen rapidly and precisely coordinates expression of its molecular circuitry to engage expression of an array of genes necessary to encode the molecular structures and effectors that rearrange host actin dynamics, we uncovered three new targets and two different molecular mechanisms of action of the GlmY and GlmZ sRNAs (Figure 4.11). Post-transcriptional regulation allows for more plasticity and rapid responses in gene expression within cells. While research into post-transcriptional regulation of genes in bacteria is a growing field, very little is known about the details of post-transcriptional regulation of virulence genes in pathogens at the bacterial/host interface.




Figure 4.11: Cartoon diagram of the proposed model of GlmY and GlmZ regulation of *LEE4*, *LEE5*, and *EspFu*. QseB and QseF activate the transcription of GlmY which stabilizes GlmZ. GlmZ activates the translation of *espFu* and destabilizes parts of the *LEE4* and *LEE5* transcripts.

Post transcriptional regulation of bacterial virulence gene expression

Our data establish that both the LEE and *espFu* genes necessary for pedestal formation on epithelial cells are post-transcriptionally regulated by the GlmY/GlmZ sRNAs through two different mechanisms. Several previous reports recognized that the LEE region is highly post-transcriptionally regulated (19, 20, 29, 122, 123, 205). However, no sRNA has yet been shown to be responsible for this regulation. One system known to be involved is the RNA binding protein and global regulator CsrA, which directly binds to the *LEE4* operon, and indirectly regulates a wide array of virulence factors (19). Additionally, the RNA chaperone Hfq is required for the proper expression of many virulence genes (81, 107, 205), suggesting that *trans*-acting sRNAs are involved at some level of regulation. Here we described the first known sRNAs that regulate the LEE, GlmY and GlmZ. Previous to this work, GlmY and GlmZ had only one target, the *glmS* mRNA, and one known molecular mechanism of action. GlmY was described as a molecular mimic of GlmZ, protecting GlmZ from degradation. In the case of *glmS*, GlmZ is the “effector sRNA” base pairing with the *glmS* mRNA to break a hairpin loop to expose the RBS and promote translation of this gene (71, 238). Our data unraveled two new mechanisms of action for these sRNAs. GlmY and Z promote cleavage of the intergenic region between *espJ* and *espFu* to allow translation of EspFu (Figure 4.2). Moreover, through destabilization of the *LEE4* and *LEE5* transcripts, these sRNAs fine tune LEE expression (Figures 4.4, 4.5 and 4.7).

Co-option of a metabolic regulatory pathway

GlmZ is well characterized as the activator of *glmS* translation. This core metabolism regulating sRNA was co-opted to regulate the LEE and *espFu*, both horizontally acquired islands, at some point in evolutionary history. Horizontal acquisition of pathogenicity islands (PAI) contributes to virulence of an organism, allowing exploitation of other niches and hosts for colonization (159). Our results suggest that the interplay between ancient and recent evolutionary acquisitions has shaped EHEC pathogenicity. An inverse example of this phenomenon comes from the InvR sRNA from *Salmonella enterica* (240), where a co-opted sRNA that is adjacent to the SPI-1 pathogenicity island regulates many core chromosomal genes.

While we did not directly observe regulation of *glmS* by GlmZ in any conditions we assayed in EHEC, we have evidence from the $\Delta qseF$ transcriptome that suggests amino sugar metabolism, and cell wall synthesis are still affected at some level in this mutant (181). The tying of glucosamine synthesis to inter-kingdom chemical signaling and pathogenesis may reflect the need to integrate both host and bacterial physiological cues to ensure a successful association between these organisms. It is also noteworthy that the LEE encoded T3SS must span the periplasm and pass through the peptidoglycan layer. Since EHEC creates dozens of these injectisomes, there is likely significant remodeling of the cell wall during host infection.

Timing and dynamics of infection

One of the key advantages of post-transcriptional regulation for an organism is it is faster than regulation at the level of transcription, allowing for much finer tuning of gene expression. In the case of GlmY and GlmZ, it also allows for the differential regulation of genes within the *LEE4* and *LEE5* operons. This decoupling of the regulation of the genes of a polycistronic mRNA from each other enables a much more varied pattern of gene expression. EHEC infection of an epithelial cell, is a prolonged and dynamic process with the bacteria growing and replicating while adhering to the pedestal. GlmZ specifically down regulates the downstream portion of the *LEE4* operon, including the filament EspA, the pore EspDB and the needle EscF, while leaving SepL unaffected (Figure 4.9). SepL is an important regulator of the translocation of effectors (48) and is likely required for effector delivery to host cells even when many of the structural proteins of the T3SS translocon are not. The post-transcriptional regulation of *LEE4* mediate by GlmZ enables EHEC to tightly regulate the process of AE lesion formation (Figures 4.2-4.9).

CHAPTER FIVE

Post-transcriptional regulation by GlmY and GlmZ in enterohemorrhagic *E. coli*

INTRODUCTION

Enterohemorrhagic *Escherichia coli* (EHEC) must precisely time the expression of its virulence genes to successfully infect its host and attach to intestinal epithelial cells. From the initial infection event the bacteria must pass through the acidic stomach, traverse the small intestine and then infect the colonic epithelium. This requires the assembly of two complex proteinaceous machines, first the flagella that it uses to cross the mucosal layer and then the LEE T3SS that is required to form the AE lesion. These systems are regulated by the Qse cascade, which also controls the expression of the sRNAs GlmY which stabilizes another sRNA GlmZ. Post-transcriptional control is faster than transcriptional control and is often used to fine tune gene expression. My previous work has shown that GlmY and GlmZ are involved in the post-transcriptional control of selective parts of the LEE with GlmZ directly binding and destabilizing part of *LEE4*. GlmZ also activates the translation of GlmS, glucosamine synthetase. Multiple targets are common in bacteria, and it is possible that GlmZ has other targets. Additionally, there is some evidence that indicates that GlmY has another function besides stabilizing GlmZ.

Trans-encoded sRNAs such as GlmY and GlmZ can act as global regulators in bacteria (236). Identifying these trans-encoded sRNAs has been facilitated due to advances in next generation sequencing technology (194). However, identifying their targets has proven to be more challenging. In some cases, such as GlmY and GlmZ, simple

overexpression of the sRNA was sufficient in revealing a target, as overexpression of either in the strain MC4100 resulted in GlmS being visible on a Coomassie stained protein gel (238). Bioinformatics have proven useful in many cases, but there are limitations. Many of the more effective approaches use evolutionary conservation of sequences to find targets (242). While this works well for core metabolism and other highly conserved genes, for horizontally acquired genes such as pathogenicity islands, there usually are too few species to make this method effective. In cases such as this, global analysis of the transcriptome is often more effective to determine the targets of sRNAs. The aim of this work is to use RNA sequencing and microarray technology to identify other GlmY and GlmZ targets in EHEC.

RESULTS

Global targets of GlmY and GlmZ

In order to determine other GlmY and GlmZ targets, several transcriptome analyses were performed. Transcripts from wt, $\Delta glmY$, and $\Delta glmZ$ were analyzed by RNA sequencing. The Nugene Ovation RNA-Seq System was used in conjunction with the Nugene RNA Encore Complete RNA-Seq system to create a library enriched in mRNA transcripts that was sequenced on an Illumina machine. This resulted in ~40 million paired reads per sample that were then analyzed using Rockhopper (131).

Many genes of the LEE pathogenicity island were upregulated in $\Delta glmY$ and $\Delta glmZ$, with *ler* being an interesting exception in $\Delta glmZ$ (Figure 5.1A). A few of the *mur* cell wall synthesis genes were affected in the RNAseq data, but failed to be confirmed by qPCR

(Figure 5.1B). It was expected that some of these would be regulated due to GlmZ's interaction with GlmS. Many stress-related genes such as the gene encoding the osmotic stress protein OsmY and the acid resistance *gad* genes were down regulated in both mutants. The fucose utilization genes, which have been associated with virulence regulation in EHEC (165), were all upregulated. The *tnaLAB* tryptophanase operon was also very strongly regulated (Figure 5.1A).

Two of the most strongly regulated genes were the outer membrane protein *nlpD* and the alternative sigma factor *rpoS* (Figure 5.1B). The *rpoS* promoter overlaps with the open reading frame of *nlpD*, and the alignment of reads to the genome showed that this difference is due to this promoter and not regulation of *nlpD* itself (Figure 5.1C).




Figure 5.1: RNA seq for Δ glmY and Δ glmZ. (A) Heat maps of stress proteins, virulence genes, fucose utilization genes, cell wall metabolism. (B) qPCR of various hits from the RNA seq data. The stress protein *osmY* was confirmed, however none of the cell wall metabolism genes were affected. (C) Alignment of RNA seq reads to the genome showing that it is *rpoS*, not *nlpD* that is differentially regulated in the Δ glmZ strain.

RpoS

The resultant pattern of expression closely matched the transcriptome pattern previously reported for an *rpoS* knockout in the EHEC strain EDL933, suggesting that many, if not most, of the difference in gene expression seen in the RNA seq data may be due to regulation of *rpoS* (50). RpoS is regulated post-transcriptionally by three separate trans-encoded sRNAs, OxyS, RprA, and DsrA (12). It is regulated transcriptionally by the ArcA-ArcB and BarA-UvrY two component systems and Crp. All of these were unaffected in the $\Delta glmY$ and $\Delta glmZ$ microarrays, as were their known transcriptional regulators.

To further investigate this, RpoS transcriptional and translation fusions were constructed. The transcriptional fusion proved to be nonviable in EHEC, however the




Figure 5.2: Regulation of *rpoS* in $\Delta glmYZ$. (A) Translational reporter fusion of RpoS::LacZ in wt, $\Delta glmY$, $\Delta glmZ$, $pglmY$, and $pglmZ$ showing no difference in expression levels (B) qPCR of *rpoS* levels in wt, $\Delta glmZ$, and $\Delta rpoS$. RpoS levels in the *glmZ* mutant are down 20-fold and for comparison are down 10,000-fold in the *rpoS* mutant. (C) Sequence alignment of the *rpoS* promoter region from wt 86-24, $\Delta glmY$, and $\Delta glmZ$ shows the same 57bp deletion in both mutants.

expression of a RpoS:LacZ translation reporter was unaffected in both the *glmY* and *glmZ* knockouts and overexpression of the two sRNAs (Figure 5.2A). The *rpoS* gene and promoter often spontaneously undergo mutagenesis. To test for this possibility, the entire region was sequenced from wt 86-24 and the $\Delta glmY$ and $\Delta glmZ$ strains (Figure 5.2C). Both sRNA knockout strains possess the same 57bp deletion. This deletion covers the -35 and -10 sequences, effectively destroying the *rpoS* promoter. However, *rpoS* is also transcribed from

the *nlpD* promoter, resulting in a knockdown phenotype in the $\Delta glmYZ$ strains with approximately 5% of wildtype levels (Figure 5.2B).

Since the $\Delta glmY$ and Z are also *rpoS* knockdowns, it is necessary to determine which of the phenotypes observed are due to a deficit of *rpoS* and which are due to the lack of the sRNAs. FAS of the *rpoS* mutant was performed and it over attaches to HeLa cells in a phenotype similar to the strain $\Delta glmZ$. (Figure 5.3A). qPCR comparing the expression of virulence genes between $\Delta glmZ$ and $\Delta rpoS$ was also performed. The expression levels of *espA*, *tir*, and *eae* were higher in both strains; however, the levels in $\Delta rpoS$ were far higher than in the *glmZ* mutant, while *stx2* levels were unaffected in both (Figure 5.3B).

Interestingly, expression of the gene encoding the LEE master regulator differs between the $\Delta glmZ$ and $\Delta rpoS$. Expression of *ler* was elevated in the $\Delta rpoS$ strain, but there was no statistically significant increase in $\Delta glmZ$ (Figure 5.3B). These data, coupled with the observation that the *glmZ* mutant can be complemented by providing GlmZ *in trans* (Figure 5.3A), suggests that the $\Delta glmZ$ and $\Delta rpoS$ phenotypes are partially overlapping, and that post-transcriptional regulation of *LEE4* and *LEE5* by GlmZ does not involve RpoS.




Figure 5.3: Comparison of $\Delta glmZ$ and $\Delta rpoS$. (A) FAS of wt EHEC, of $\Delta glmZ$, $\Delta glmZ pglmZ$ and $\Delta rpoS$. The $\Delta glmZ$ and $\Delta rpoS$ strains both overattach to HeLa cells, however $\Delta glmZ$ is fully complementable (B) q-rtpCR of virulence gene expression in $\Delta glmZ$ and $\Delta rpoS$. *ler* is stastically unchanged in $\Delta glmZ$ and up in $\Delta rpoS$. *espA*, *tir*, and *eae* are up in both mutants, although significantly more in the $\Delta rpoS$ strain. *Stx2* expression is unchanged

In order to determine which of the targets identified from the RNA seq transcriptome are actually due to $\Delta glmY$ and $\Delta glmZ$ or the $rpoS$ knockdown, we used Affymetrix GeneChip *E. coli* Genome 2.0 arrays to compare the transcripts of $\Delta glmY$ and $\Delta glmZ$ to $\Delta rpoS$, and wt to $\Delta rpoS$. The global effects are summarized in Table 5.1. There are significant differences between both $\Delta glmY$ and $\Delta glmZ$ and $\Delta rpoS$ suggesting that many of these GlmY and GlmZ regulated genes are not due to the knockdown of $rpoS$ in the $glmY$ or $glmZ$ mutants. Hence,

Comparison	$\Delta glmY$ vs $\Delta rpoS$	$\Delta glmZ$ vs $\Delta rpoS$	$\Delta glmY$ vs $\Delta glmZ$	wt vs $\Delta rpoS$
Increase	781	669	676	1121
Marginally Increase	61	42	415	62
No Change	8281	7848	8399	7779
Marginally Decrease	72	93	58	61
Decrease	1013	1556	1034	1195
Differential Expression	1927	2360	1809	2429

Table 5.1: Table of changes in gene expression in $\Delta glmY$ and $\Delta glmZ$ vs $\Delta rpoS$

certain genes seem to be regulated by GlmY and GlmZ and not $rpoS$ (Figure 5.4A). The annotation file format used by Rockhopper excludes sRNAs, whereas the *E. coli* 2.0 array does not. The $\Delta glmY$ vs $\Delta glmZ$ microarray data revealed that many ncRNAs are enriched in $\Delta glmY$ (Figure 5.4B). GlmY is already known to stabilize GlmZ due to its interaction with RapZ. It's possible that GlmY regulates other sRNAs as well. Additionally, the maltose ABC transporter seems to be differentially regulated by GlmY and GlmZ, with mRNA levels being much higher in $\Delta glmY$ (Figure 5.4C).




Figure 5.4: Heatmaps of $\Delta glmY$ and $\Delta glmZ$ vs $\Delta rpoS$. (A) Curli genes are down in $\Delta glmY$ and $\Delta glmZ$ but not $\Delta rpoS$. (B) Various sRNAs are up regulated in $\Delta glmY$. (C) The maltose ABC transported is differentially regulated by GlmY and GlmZ

Regulation of Curli by GlmZ

One of the major pathways that the microarray data indicated was regulated in a *rpoS* independent manner by GlmY and GlmZ was curli, a major class of adhesion molecules that are involved in bacterial attachment to abiotic surfaces, biofilm formation, and attachment to host cells (12, 170). The curli genes are regulated by the transcription factor CsgD that activates the transcription of the other *csg* operons. The other components are exported to the periplasm through the sec secretion system. CsgE and CsgF stabilize the other subunits and transport them to CsgG which exports them out of the cell. Then the major subunit, CsgA, is assembled by the homologous protein CsgB (Figure 5.5A) (12).

Expression of *csgE* and *csgF* was measured by qPCR (Figure 5.5B). While there was no difference the $\Delta rpoS$ strain in the transcript, levels of both genes were decreased in the *glmZ* mutant congruent with the microarray data. Curli are capable of binding to the Congo red dye. Cells that express curli at high levels turn bright red on Congo red plates while those that cannot express curli remain white. This is a convenient assay for the detection of functional curli on bacteria cells. Wt EHEC, $\Delta glmY$, $\Delta glmZ$ and $\Delta rpoS$ were plated on Congo red plates (Figure 5.5C). Contrary to the qPCR data, the $\Delta glmZ$ strain appears to make more curli than wt EHEC. Interestingly, the $\Delta rpoS$ mutant is deficient in curli production, as previously published in K12 (79), which also conflicts with the qPCR data. In *E. coli* K12, the promoters for both operons are σ^S promoters and the sequence identity is 99%. The discrepancy between the two readouts may be due to post-transcriptional regulation.




Figure 5.5: Regulation of curli by GlmYZ. (A) Diagram of curli in *E. coli* (12). (B) qPCR of curli gene expression in wt, $\Delta glmZ$, and $\Delta rpoS$. Expression of *csgEF* is decreased in $\Delta glmZ$ but not in $\Delta rpoS$. (C) Congo red plate of wt, $\Delta glmY$, $\Delta glmZ$, and $\Delta rpoS$. Curli production is visible and unchanged in $\Delta glmY$, increased in $\Delta glmZ$, and decreased in $\Delta rpoS$.

Regulation of NleA

NleA is a non-LEE encoded type three secreted effector protein that disrupts the tight junctions of epithelial cells, which has been shown to be important for virulence in the *Citrobacter* animal model (75). While *nleA* is *rpoS* regulated according to microarray data, it was not significantly regulated our transcriptome data did not suggest it was regulated by GlmY or GlmZ independently of RpoS. In order to determine if the *nleA* regulation was solely due to the effects of *rpoS*, qPCR of the gene was performed in EHEC overexpressing the *glmY* or *glmZ* sRNA (Figure 5.6A). Expression of the *nleA* gene was decreased when either sRNA was overexpressed.




Figure 5.5: Regulation of NleA by GlmYZ. (A) qPCR of *nleA* expression in wt EHEC and strains over expressing *glmY* or *glmZ*. Overexpression of either sRNA results in decreased levels of *nleA* (B) Transcriptional *nleA* fusion in cells overexpressing *glmY* or *glmZ*. LacZ expression is unaffected by overexpression.

An *nleA::lacZ* transcriptional fusion was constructed and used to determine if the difference in the expression levels was due to effects at the level of transcription, and overexpression of *glmY* and *glmZ* had no effect. GlmY and GlmZ are likely working at the post-transcriptional level, although it may be an indirect effect.

DISCUSSION

E. coli is estimated to encode 200 small RNAs, with 55 being experimentally confirmed (86, 241). For comparison, two-component systems are considered one of the major regulator systems in bacteria and *E. coli* has only 36 (163). These sRNAs represent a major source of regulation that is largely unexplored. Most studies into *E. coli* sRNAs have used a K12 strain, so regulation of virulence genes present in pathogenic strains such as EHEC has been neglected. GlmY and GlmZ have been shown to directly regulate *glmS* (238) and *LEE4* and also *LEE5* and *espFu*. In this study we investigated the global role of GlmY and GlmZ in EHEC gene regulation.

GlmYZ and RpoS

The discovery that both $\Delta glmY$ and $\Delta glmZ$ have a deletion in the *rpoS* promoter is intriguing. While mutations in the *rpoS* gene are not uncommon, the fact that both mutants have the exact same deletion that is absent in the parent strain suggests that there is significant selection against overt *rpoS* expression in these mutants.

RpoS mutants are much more likely to become persister cells, bacterial cells that are extremely resistant to bacteriostatic antibiotics, such as those that affect the cell wall synthesis (89). Given the known role of GlmY and GlmZ in amino sugar metabolism and thus cell wall formation, it is possible that without these sRNAs the bacterial cell is under a similar form of stress at some point during their *in vitro* growth. RpoS is also known to be involved in the regulation of the LEE and other virulence genes (50). It is possible that it works in concert with GlmY and GlmZ. Both of these sRNAs are reported to be more abundant during stationary phase, suggesting that there may be a complex interplay between these regulators of virulence.

GlmY without GlmZ

To date, GlmY has only been reported to act by binding to RapZ and preventing the degradation of GlmZ (71). We previously found evidence that GlmY is capable of acting independently, as it was capable of partially complementing a $\Delta glmZ$ strain. However, GlmY does not bind Hfq, so it is unknown how it would directly act on any target.

Our RNAseq and microarray data show that the $\Delta glmY$ transcriptome has several major differences from that of $\Delta glmZ$. Interestingly, several sRNAs are much more abundant in the $\Delta glmY$. GlmY is known to stabilize GlmZ. These data suggest it is involved in the regulation of other sRNAs through a still unknown mechanism. The regulation of the maltose ABC transporter system is vastly different between $\Delta glmY$ and $\Delta glmZ$, its expression is increased in $\Delta glmY$ and decreased in $\Delta glmZ$. The glucose polymers that would result in

free maltose are a favored energy source for *E. coli* and are present in the host. Additionally, the maltose porin LamB is the lambda phage receptor. It is unclear why this system would be differentially regulated by two sRNAs in the same pathway.

Regulation of Other Virulence Genes by GlmYZ

The curli genes in EHEC have been implicated in the attachment of the bacteria to abiotic surfaces, plants, and host cells (113, 170). These genes have been reported to be regulated by RpoS in K12 (176). However, we did not observe *rpoS*-dependent regulation of *csgEF* during our assays. Instead we observed that transcript levels of *csgEF* were decreased in $\Delta glmY$ and $\Delta glmZ$, but unchanged in $\Delta rpoS$. Conversely, we observed increased curli formation on Congo red plates in $\Delta glmZ$, and the loss of curli in the $\Delta rpoS$. CsgEF are required for the formation of curli (152), suggesting that post-transcriptional control of curli transcripts results in differences in protein and mRNA levels.

EHEC has an estimated 51 effector proteins, only 6 of which are encoded within the LEE itself (231). While the LEE is the largest and most important pathogenicity island, EHEC also has several O-islands that encode for other virulence proteins such as the non-LEE encoded effectors. We have shown that GlmY and GlmZ regulate at least one of these effectors, NleA, and that this regulation is post-transcriptional. This raises the possibility that GlmYZ are global regulators of virulence in EHEC. Other O-island encoded genes will need to be investigated.

CHAPTER SIX

Conclusions and Future Directions

CONCLUSIONS

This work was focused on increasing our understanding of the downstream targets of the QseC and QseE signaling pathway, specifically the response regulator QseF. QseF was reported to activate the transcription of the gene encoding the sRNA GlmY, and we determined that the other Qse response regulator QseB also activates its transcription. GlmY is known to bind to RapZ and displace another sRNA, GlmZ preventing its degradation. GlmZ subsequently activates the translation of GlmS, glucosamine synthetase (71, 100, 184, 238). We showed that GlmY and GlmZ also regulate the translation of the effector *espFu* and post-transcriptionally regulated the *LEE4* and *LEE5* mRNA, with GlmZ directly targeting *LEE4*. While investigating the global regulation of GlmYZ using RNA sequencing, we determined that both knockouts had a mutation in *rpoS* promoter region, creating a knockdown effect, suggesting a connection between *rpoS* and *glmYZ*. We then showed that *glmY* and *glmZ* regulate expression of curli and the effector *nleA* post-transcriptionally. We also identified differences between $\Delta glmY$ and $\Delta glmZ$, specifically regarding the expression of various sRNAs and the maltose ABC transporter. Our data suggest that GlmYZ may be a global regulator of virulence in EHEC.

The role of RpoS in GlmYZ regulation

The alternative sigma factor RpoS controls a vast array of genes involved in cell survival in stationary phase, biofilm formation, metabolism, and virulence (14, 50). Mutants

for *rpoS* are common in both environmental and laboratory populations of *E. coli* and they often have a selective advantage under conditions of nutrient limitation. However *rpoS* mutants perform poorly during other stress conditions such as acid stress (157). Since both the *glmY* and *glmZ* mutants have a conserved deletion in the *rpoS* promoter, it is likely that the *glmY* and *glmZ* mutants nonviable when *rpoS* is expressed at normal levels. This may be due to the enhanced ability of *rpoS* mutants to enter a persister state (89). Persister cells are in a largely dormant state, and are capable of surviving antibiotic treatment (204). As *glmYZ* are known to regulate *glmS* and thus amino sugar metabolism and cell wall biogenesis, it is possible that the lack of these sRNAs causes a similar stress to the cell. While we did not observe *glmS* regulation by GlmZ in the growth conditions we tested in EHEC, the sequence of GlmZ and *glmS* that interact are identical and the *qseF* array (181) suggests it still occurs at some point during the growth phase (181). An alternative possibility that is equally supported by our data is that *glmYZ* and *rpoS* have overlapping regulation, and that in the absence of *glmY* or *glmZ*, *rpoS* is toxic due to other factors. The *glmZ* mutant, which contains the *rpoS* promoter deletion, was complemented by *glmZ* on a plasmid, which suggests that GlmZ has RpoS-independent functions.

Post transcriptional regulation of bacterial virulence genes

We have shown that the required genes for pedestal formation are post-transcriptionally regulated by GlmYZ. The *espJ-espFu* mRNA undergoes a processing event in a manner somewhat reminiscent of the *gadWX* operon (161, 234). This processing event

requires GlmYZ and is needed for efficient expression of *espFu*. Additionally, the latter fragments of both *LEE4* and *LEE5* operons are downregulated by GlmYZ, which in the case of *LEE4* is due to direct binding of GlmZ to the *orf29* region of *LEE4*. GlmYZ are also able to downregulate the expression of the effector *nleA* in a post-transcriptional manner. The curli genes also seem to be regulated by GlmY and GlmZ. The transcript levels of curli genes are decreased in the *glmYZ* mutants in both the microarray data and according to qPCR; however, according to Congo red plates, curli production is increased. There are multiple possibilities for this discrepancy; there could be post-transcriptional regulation or differences in gene expression due to different growth conditions, static cultures vs. plates. It is also possible that these sRNAs are involved in the timing of curli expression, decreasing translation once enough curli have been expressed, and perhaps promoting stabilization of curli proteins through regulation of chaperones. These data all suggest that GlmYZ play an important role in virulence gene regulation (Figure 6.1).




Figure 6.1: Virulence gene regulation by GlmYZ. Cartoon diagram of the proposed model of GlmY and GlmZ regulation of LEE4, LEE5, NleA and EspFu. QseB and QseF activate transcription of GlmY which stabilizes GlmZ. GlmZ activates the translation of *espFu* and destabilizes *LEE4* and *LEE5*. GlmY and GlmZ also downregulate *nleA* post-transcriptionally and are involved in the regulation of curli expression.

GlmY vs. GlmZ

Currently, the only published role for GlmY is to act as an anti-adaptor RNA to prevent GlmZ degradation (71). GlmY and GlmZ are both conserved in other enterobacteria, suggesting that this pathway is also conserved (70). This system may exist to allow for multiple levels of control to regulate GlmZ function. Alternatively GlmY may have a function apart from GlmZ. Our transcriptome data show that there are many differences in gene expression between $\Delta glmY$ and $\Delta glmZ$. The most strongly differentially regulated

genes are those of the maltose ABC transporter, which are slightly increased in $\Delta glmY$ and strongly decreased in $\Delta glmZ$. This system is responsible for the uptake of $\alpha(1\rightarrow4)$ glucose polymers of 7-8 monomers in length, which are degradation products of many common polysaccharides including amylose and glycogen. The maltose porin, LamB, is also the receptor for the lambda phage (21). It is currently unclear why or how *glmY* would regulate these genes. The known target of the GlmY/Z pathway, *glmS*, is involved in sugar metabolism, so this may be the link with maltodextrins. Trans-acting sRNAs such as GlmZ lack perfect sequence complementarity and require the RNA chaperone Hfq to act. GlmY is incapable of binding Hfq (47), so its mechanism of action is likely distinct from other reported sRNAs.

Our microarray data also indicate that many sRNAs are differentially regulated between $\Delta glmY$ and $\Delta glmZ$. The only known function of GlmY is to stabilize GlmZ, however our data show that other sRNAs are destabilized in the absence of GlmY. The RNase E binding protein RapZ is responsible for the degradation of GlmZ has only been found to bind to GlmY and GlmZ (71). This suggests that the mechanism that GlmY uses to affect the stability of other sRNAs is potentially through a different mechanism. All of these data, along with our finding that GlmY can partially complement a *glmZ* KO (Figure 4.4B) show that *glmY* can act through a *glmZ* independent mechanism.

Tying metabolism to virulence

The activation of translation of GlmS by GlmZ is well studied. The regulation of this essentially metabolic pathway was co-opted to regulate horizontally acquired virulence genes. To be useful to the cell, these newly acquired genes must be integrated into the bacteria's genetic machinery. There are many known examples of core metabolism transcription factors that have been coopted to regulate virulence genes (10), but GlmY and GlmZ are the first reported sRNAs to do so.

While we did not find any direct evidence of *glmS* regulation in EHEC under the growth conditions we tested, microarray data from $\Delta qseF$ suggests that it does occur. Additionally, our results also tie this system to maltose uptake. Metabolism and virulence are intimately intertwined in EHEC and other pathogens (155, 156, 165), and GlmYZ are another example of this. In this case the bacteria tied both glucosamine and pathogenesis to interkingdom signaling. This may be advantageous for EHEC since the LEE T3SS must cross the periplasm and the peptidoglycan cell wall, which would require significant remodeling of the cell wall.

Timing is everything

Post-transcriptional regulation has many advantages. It is faster than transcriptional control and it allows for differential regulation of different genes within an operon. This uncoupling of transcription from gene expression allows for greater control of polycistronic mRNAs. We showed that GlmY and GlmZ specifically down regulate parts of the *LEE4* and *LEE5* operons. GlmZ destabilize the portions of *LEE4* that encode the EspA filament, the

EspDB, and the EscF needle while leaving SepL unaffected. In the case of *LEE5*, GlmY and GlmZ downregulate the chaperone CesT and the adhesin intimin while leaving the translocated intimin receptor Tir alone. In both cases, the genes that are downregulated are likely genes that are needed earlier in the infection. For *LEE5*, CesT and intimin both stay associated with the bacteria cell while Tir enters the host cell. In the case of *LEE4*, EspADB and EscF are required for the assembly of the needle and the translocon while SepL is required for the regulation of effector secretion. The process of infecting an epithelial cell and forming an AE lesion requires tight control of several layers of gene expression and the post-transcriptional regulation of these two operons is likely responsible for the fine tuning of this process.

GlmY is regulated by the quorum sensing QseEC kinase systems, and previous work has shown that this system is central to the regulation of virulence genes in EHEC. (37, 38, 90, 154, 156, 182, 219). My work has added the GlmYZ sRNA cascade to this regulon (Figure 6.2).




Figure 6.2: QseEC cascade and GlmYZ. Cartoon model of cell to cell signaling regulation of virulence genes through GlmYZ. QseC and QseE sense bacterial and host derived signaling molecules and phosphorylate three different response regulators, KdpE, QseB, and QseF. KdpE activates expression of *ler*, which then activates the rest of the LEE, forming the T3SS. QseB and QseF both activate the transcription of GlmY and thus increase the levels of GlmZ. GlmZ activates the translation of *espFu*, which with the rest of the T3SS is required for pedestal formation. GlmZ also destabilizes the mRNAs for the structural genes of the LEE, selectively turning off gene expression.

FUTURE DIRECTIONS

While my studies have shown that GlmY and GlmZ are important regulators of virulence in EHEC, there is much work that still needs to be done. While QseB and QseF both regulate *glmY*, there is nothing known about the transcriptional regulation of *glmZ*, except that QseF and QseB are not involved. Additionally, the factors that lead to the accumulation of *glmY* in glucosamine limiting conditions are also unknown, as are regulators of *rapZ*. To fully understand the context of GlmY and GlmZ regulation, more information on the regulation of this pathway is needed.

We discovered that the $\Delta glmY$ and $\Delta glmZ$ both contained the same deletion in the *rpoS* promoter region. This is extremely unlikely to have happened by chance, so there must be some very strong selection for this. To test this, we will need to restore *rpoS* to wildtype levels in the $\Delta glmY$ and $\Delta glmZ$ strains, and determine if they have a growth defect or are viable. If expression of *rpoS* does not kill these bacteria, it would also be interesting to attempt to recreate these mutants and isolate clones that do not have this mutation. The $\Delta rpoS$ phenotype has some similarities to that of $\Delta glmYZ$, but there are also differences between the two that need to be further investigated. Since *glmZ* on a plasmid complemented all of the *glmZ* mutant phenotypes assessed, this suggests that there several GlmZ targets are independent of RpoS. Additionally, since the *glmY* and *glmZ* mutants do express some *rpoS* from the *nlpD* promoter, a construct that mimics this level of expression should be constructed and used to complement the *rpoS* mutant. These data suggest the intriguing possibility that these sRNAs are important for the proper function of the *rpoS* regulon, and that in the absence of these sRNAs, overt RpoS expression is deleterious to the bacteria cell.

Our data have raised the possibility that GlmY has a role independent of GlmZ. The FAS data of the *glmY* and *glmZ* mutants first suggested this as overexpressing *glmY* partially complemented the Δ *glmZ* phenotype. Overexpression of Hfq-binding sRNAs often have pleiotropic effects due to the sequestration of Hfq. However GlmY cannot bind Hfq, making this scenario unlikely. The regulation of the maltose operon provides another example of GlmY being involved in sugar metabolism in a GlmZ independent manner. More work is needed to determine if this is a direct interaction, and if it is at the transcriptional or translational level. The effect of *glmY* on many other sRNAs also suggests that *glmY* may act as a global regulator of other sRNAs. The only known way to affect so many sRNAs at once is to affect Hfq (47), because in its absence most trans-acting sRNAs are destabilized. Hence the effect of GlmY on the transcription and translation of Hfq needs to be assessed.

We showed that GlmY and GlmZ regulate virulence genes in EHEC. The *espJ-espFu* mRNA is processed in a QseF dependent manner, and its expression can be restored through overexpression of *glmY* or *glmZ*. Investigations into the regulation of *espFu* are complicated by the extremely low expression of this effector. The only way this protein can be detected by western blot is in an artificial system where the pUC plasmid is used to have several hundred copies of the gene per cell. An enzymatic reporter system such as LacZ may be better suited to study *espFu*. We determined that GlmZ directly binds to *LEE4*; however we have not identified the ribonuclease responsible. RNase E, the primary RNase in *E. coli* had no effect. The secondary RNase, RNase III, has also been known to act on the targets of various sRNAs. We successfully constructed an *rnc* (RNase III) mutant, however while this

gene is not essential, the mutant is extremely ill and has severe growth defects. There is no temperature sensitive allele, so an inducible promoter construct needs to be made so expression of *mnc* can be shut off at will. While we showed that GlmZ regulates *LEE5*, we were unable to find a direct interaction site. Bioinformatics have not worked, so a more brute force approach may be necessary. For example, fragments of the *LEE5* operon can be cloned into a reporter until the region is found. As *glmY* and *glmZ* overexpression downregulate NleA post-transcriptionally, a translation fusion of the gene will need to be made to determine if it is regulated akin to *LEE4* or GlmS. Expression of other non-LEE encoded effectors should also be investigated since the microarray and RNA seq data did not reliably identify NleA as being regulated by GlmYZ. The *rpoS/glmYZ* regulation of curli is contradictory. The expression of *csgA*, the major structural protein and *csgD*, the master regulator will need to be investigated. It is possible that this discrepancy is simply due to the differences in gene expression on an agar plates vs. statically at 37°C and 5% CO₂, or that there is differential regulation of transcript and protein levels by these sRNAs.

To study the role of *glmY* and *glmZ* in pathogenesis *in vivo*, the *Citrobacter rodentium* model could be used. The *Citrobacter* genomic sequence reveals that GlmY and GlmZ are conserved and have the same promoter elements, in contrast to other species such as *Salmonella* where *glmZ* has a σ^{54} promoter (70). The main difficulty would be constructing the knockouts of the genes, preferably avoiding the *rpoS* promoter deletion. This system may function similarly with the *Citrobacter* LEE, making it a useful infection

model. Our data indicate that GlmY and GlmZ are key regulators of virulence in EHEC, and this study has laid the groundwork for future investigations.

REFERENCES

1. Abe A, *et al.* (1999) Enteropathogenic Escherichia coli translocated intimin receptor, Tir, requires a specific chaperone for stable secretion. *Mol Microbiol* 33(6):1162-1175.
2. Ahmer BM (2004) Cell-to-cell signalling in Escherichia coli and Salmonella enterica. *Molecular microbiology* 52(4):933-945.
3. Aiba H (2007) Mechanism of RNA silencing by Hfq-binding small RNAs. *Current opinion in microbiology* 10(2):134-139.
4. Alto NM, *et al.* (2006) Identification of a bacterial type III effector family with G protein mimicry functions. *Cell* 124(1):133-145.
5. Ancona V, Li W, & Zhao Y (2013) Alternative sigma factor RpoN and its modulation protein YhbH are indispensable for Erwinia amylovora virulence. *Molecular plant pathology*.
6. Anders S & Huber W (2010) Differential expression analysis for sequence count data. *Genome biology* 11(10):R106.
7. Andrade A, Pardo JP, Espinosa N, Perez-Hernandez G, & Gonzalez-Pedrajo B (2007) Enzymatic characterization of the enteropathogenic Escherichia coli type III secretion ATPase EscN. *Archives of biochemistry and biophysics* 468(1):121-127.
8. Apirion D (1978) Isolation, genetic mapping and some characterization of a mutation in Escherichia coli that affects the processing of ribonucleic acid. *Genetics* 90(4):659-671.
9. Babitzke P & Romeo T (2007) CsrB sRNA family: sequestration of RNA-binding regulatory proteins. *Current opinion in microbiology* 10(2):156-163.
10. Baek CH, Wang S, Roland KL, & Curtiss R, 3rd (2009) Leucine-responsive regulatory protein (Lrp) acts as a virulence repressor in Salmonella enterica serovar Typhimurium. *Journal of bacteriology* 191(4):1278-1292.
11. Barba J, *et al.* (2005) A positive regulatory loop controls expression of the locus of enterocyte effacement-encoded regulators Ler and GrlA. *Journal of bacteriology* 187(23):7918-7930.
12. Barnhart MM & Chapman MR (2006) Curli biogenesis and function. *Annual review of microbiology* 60:131-147.
13. Bassler BL, Wright M, & Silverman MR (1994) Multiple signalling systems controlling expression of luminescence in Vibrio harveyi: sequence and function of genes encoding a second sensory pathway. *Molecular microbiology* 13(2):273-286.
14. Battesti A, Majdalani N, & Gottesman S (2011) The RpoS-mediated general stress response in Escherichia coli. *Annual review of microbiology* 65:189-213.
15. Bauer ME & Welch RA (1996) Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7. *Infection and immunity* 64(1):167-175.
16. Bell BP, *et al.* (1994) A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. *JAMA : the journal of the American Medical Association* 272(17):1349-1353.
17. Berger CN, *et al.* (2012) EspZ of enteropathogenic and enterohemorrhagic Escherichia coli regulates type III secretion system protein translocation. *mBio* 3(5).

18. Bertrand K, Squires C, & Yanofsky C (1976) Transcription termination in vivo in the leader region of the tryptophan operon of *Escherichia coli*. *Journal of molecular biology* 103(2):319-337.
19. Bhatt S, *et al.* (2009) The RNA binding protein CsrA is a pleiotropic regulator of the locus of enterocyte effacement pathogenicity island of enteropathogenic *Escherichia coli*. *Infection and immunity* 77(9):3552-3568.
20. Bhatt S, Romeo T, & Kalman D (2011) Honing the message: post-transcriptional and post-translational control in attaching and effacing pathogens. *Trends Microbiol* 19(5):217-224.
21. Boos W & Shuman H (1998) Maltose/maltodextrin system of *Escherichia coli*: transport, metabolism, and regulation. *Microbiology and molecular biology reviews : MMBR* 62(1):204-229.
22. Brunder W, Schmidt H, & Karch H (1997) EspP, a novel extracellular serine protease of enterohaemorrhagic *Escherichia coli* O157:H7 cleaves human coagulation factor V. *Molecular microbiology* 24(4):767-778.
23. Brunder W, Schmidt H, & Karch H (1996) KatP, a novel catalase-peroxidase encoded by the large plasmid of enterohaemorrhagic *Escherichia coli* O157:H7. *Microbiology* 142 (Pt 11):3305-3315.
24. Burland V, *et al.* (1998) The complete DNA sequence and analysis of the large virulence plasmid of *Escherichia coli* O157:H7. *Nucleic acids research* 26(18):4196-4204.
25. Busch A, Richter AS, & Backofen R (2008) IntaRNA: efficient prediction of bacterial sRNA targets incorporating target site accessibility and seed regions. *Bioinformatics* 24(24):2849-2856.
26. Bush M & Dixon R (2012) The role of bacterial enhancer binding proteins as specialized activators of sigma54-dependent transcription. *Microbiology and molecular biology reviews : MMBR* 76(3):497-529.
27. Bustamante VH, Santana FJ, Calva E, & Puente JL (2001) Transcriptional regulation of type III secretion genes in enteropathogenic *Escherichia coli*: Ler antagonizes H-NS-dependent repression. *Molecular microbiology* 39(3):664-678.
28. Campellone KG, Robbins D, & Leong JM (2004) EspFU is a translocated EHEC effector that interacts with Tir and N-WASP and promotes Nck-independent actin assembly. *Dev Cell* 7(2):217-228.
29. Campellone KG, *et al.* (2007) Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic *Escherichia coli* O157:H7. *Mol Microbiol* 63(5):1468-1481.
30. Caron E, *et al.* (2006) Subversion of actin dynamics by EPEC and EHEC. *Curr Opin Microbiol* 9(1):40-45.
31. Carver T, *et al.* (2013) BamView: visualizing and interpretation of next-generation sequencing read alignments. *Briefings in bioinformatics* 14(2):203-212.
32. Centers for Disease C & Prevention (2005) Outbreaks of *Escherichia coli* O157:H7 associated with petting zoos--North Carolina, Florida, and Arizona, 2004 and 2005. *MMWR. Morbidity and mortality weekly report* 54(50):1277-1280.
33. Chen B, Sysoeva TA, Chowdhury S, & Nixon BT (2008) Regulation and action of the bacterial enhancer-binding protein AAA+ domains. *Biochemical Society transactions* 36(Pt 1):89-93.
34. Chinen I, *et al.* (2001) Isolation and characterization of *Escherichia coli* O157:H7 from retail meats in Argentina. *Journal of food protection* 64(9):1346-1351.

35. Clarke MB, Hughes DT, Zhu C, Boedeker EC, & Sperandio V (2006) The QseC sensor kinase: A bacterial adrenergic receptor. *Proc Natl Acad Sci U S A*.
36. Clarke MB, Hughes DT, Zhu C, Boedeker EC, & Sperandio V (2006) The QseC sensor kinase: A bacterial adrenergic receptor. *Proc Natl Acad Sci U S A* (103):10420-10425.
37. Clarke MB, Hughes DT, Zhu C, Boedeker EC, & Sperandio V (2006) The QseC sensor kinase: a bacterial adrenergic receptor. *Proceedings of the National Academy of Sciences of the United States of America* 103(27):10420-10425.
38. Clarke MB & Sperandio V (2005) Transcriptional regulation of flhDC by QseBC and sigma (FliA) in enterohaemorrhagic Escherichia coli. *Molecular microbiology* 57(6):1734-1749.
39. Clements A, et al. (2011) EspG of enteropathogenic and enterohemorrhagic E. coli binds the Golgi matrix protein GM130 and disrupts the Golgi structure and function. *Cellular microbiology* 13(9):1429-1439.
40. Corrigan JJ, Jr. & Boineau FG (2001) Hemolytic-uremic syndrome. *Pediatrics in review / American Academy of Pediatrics* 22(11):365-369.
41. Crane JK, McNamara BP, & Donnenberg MS (2001) Role of EspF in host cell death induced by enteropathogenic Escherichia coli. *Cell Microbiol* 3(4):197-211.
42. Creasey EA, et al. (2003) CesT is a bivalent enteropathogenic Escherichia coli chaperone required for translocation of both Tir and Map. *Molecular microbiology* 47(1):209-221.
43. Creasey EA, et al. (2003) CesAB is an enteropathogenic Escherichia coli chaperone for the type-III translocator proteins EspA and EspB. *Microbiology* 149(Pt 12):3639-3647.
44. Crepin VF, et al. (2005) Structural and functional studies of the enteropathogenic Escherichia coli type III needle complex protein EscJ. *Molecular microbiology* 55(6):1658-1670.
45. Daniell SJ, et al. (2001) The filamentous type III secretion translocon of enteropathogenic Escherichia coli. *Cellular microbiology* 3(12):865-871.
46. Datsenko KA & Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. *Proceedings of the National Academy of Sciences of the United States of America* 97(12):6640-6645.
47. De Lay N, Schu DJ, & Gottesman S (2013) Bacterial small RNA-based negative regulation: Hfq and its accomplices. *The Journal of biological chemistry* 288(12):7996-8003.
48. Deng W, et al. (2005) Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens. *Infection and immunity* 73(4):2135-2146.
49. Deng W, et al. (2004) Dissecting virulence: systematic and functional analyses of a pathogenicity island. *Proc Natl Acad Sci U S A* 101(10):3597-3602.
50. Dong T & Schellhorn HE (2009) Global effect of RpoS on gene expression in pathogenic Escherichia coli O157:H7 strain EDL933. *BMC genomics* 10:349.
51. Donnenberg MS, et al. (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. *The Journal of clinical investigation* 92(3):1412-1417.
52. Donnenberg MS, et al. (1993) The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. *The Journal of clinical investigation* 92(3):1418-1424.
53. Eaton KA, et al. (2008) Pathogenesis of renal disease due to enterohemorrhagic Escherichia coli in germ-free mice. *Infection and immunity* 76(7):3054-3063.

54. Elliott SJ, *et al.* (1999) Identification of CesT, a chaperone for the type III secretion of Tir in enteropathogenic *Escherichia coli*. *Molecular Microbiology* 33(6):1176-1189.
55. Elliott SJ, *et al.* (1999) Identification of CesT, a chaperone for the type III secretion of Tir in enteropathogenic *Escherichia coli*. *Molecular microbiology* 33(6):1176-1189.
56. Elliott SJ, *et al.* (2001) EspG, a novel type III system-secreted protein from enteropathogenic *Escherichia coli* with similarities to VirA of *Shigella flexneri*. *Infect Immun* 69(6):4027-4033.
57. Elliott SJ, *et al.* (2002) A gene from the locus of enterocyte effacement that is required for enteropathogenic *Escherichia coli* to increase tight-junction permeability encodes a chaperone for EspF. *Infection and immunity* 70(5):2271-2277.
58. Elliott SJ, *et al.* (1998) The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic *Escherichia coli* E2348/69. *Molecular microbiology* 28(1):1-4.
59. Endo Y, *et al.* (1988) Site of action of a Vero toxin (VT2) from *Escherichia coli* O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. *European journal of biochemistry / FEBS* 171(1-2):45-50.
60. Engebrecht J & Silverman M (1984) Identification of genes and gene products necessary for bacterial bioluminescence. *Proceedings of the National Academy of Sciences of the United States of America* 81(13):4154-4158.
61. Escherich T (1885) Die darmbakterien des neugeborenen und säuglings. *Fortschritte der Medizin* 3:515-522.
62. Fraser ME, *et al.* (2004) Structure of shiga toxin type 2 (Stx2) from *Escherichia coli* O157:H7. *The Journal of biological chemistry* 279(26):27511-27517.
63. Friedberg D, Umanski T, Fang Y, & Rosenshine I (1999) Hierarchy in the expression of the locus of enterocyte effacement genes of enteropathogenic *Escherichia coli*. *Molecular microbiology* 34(5):941-952.
64. Fuqua C (2006) The QscR quorum-sensing regulon of *Pseudomonas aeruginosa*: an orphan claims its identity. *Journal of bacteriology* 188(9):3169-3171.
65. Garcia-Sastre A & Sansonetti PJ (2010) Host-pathogen interactions. *Curr Opin Immunol* 22(4):425-427.
66. Garmendia J, *et al.* (2004) TccP is an enterohaemorrhagic *Escherichia coli* O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton. *Cellular microbiology* 6(12):1167-1183.
67. Gauthier A, Puente JL, & Finlay BB (2003) Secretin of the enteropathogenic *Escherichia coli* type III secretion system requires components of the type III apparatus for assembly and localization. *Infection and immunity* 71(6):3310-3319.
68. Ghosh S, Blumenthal HJ, Davidson E, & Roseman S (1960) Glucosamine metabolism. V. Enzymatic synthesis of glucosamine 6-phosphate. *The Journal of biological chemistry* 235:1265-1273.
69. Goldberg MD, Johnson M, Hinton JC, & Williams PH (2001) Role of the nucleoid-associated protein Fis in the regulation of virulence properties of enteropathogenic *Escherichia coli*. *Molecular microbiology* 41(3):549-559.
70. Gopel Y, *et al.* (2011) Common and divergent features in transcriptional control of the homologous small RNAs GlmY and GlmZ in Enterobacteriaceae. *Nucleic acids research* 39(4):1294-1309.

71. Gopel Y, Papenfort K, Reichenbach B, Vogel J, & Gorke B (2013) Targeted decay of a regulatory small RNA by an adaptor protein for RNase E and counteraction by an anti-adaptor RNA. *Genes & development* 27(5):552-564.
72. Gorke B & Vogel J (2008) Noncoding RNA control of the making and breaking of sugars. *Genes & development* 22(21):2914-2925.
73. Grant J, *et al.* (2008) Spinach-associated Escherichia coli O157:H7 outbreak, Utah and New Mexico, 2006. *Emerging infectious diseases* 14(10):1633-1636.
74. Griffin PM, *et al.* (1988) Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum. *Annals of internal medicine* 109(9):705-712.
75. Gruenheid S, *et al.* (2004) Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. *Molecular microbiology* 51(5):1233-1249.
76. Gutierrez-Preciado A, Henkin TM, Grundy FJ, Yanofsky C, & Merino E (2009) Biochemical features and functional implications of the RNA-based T-box regulatory mechanism. *Microbiology and molecular biology reviews : MMBR* 73(1):36-61.
77. Guzman LM, Belin D, Carson MJ, & Beckwith J (1995) Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *Journal of bacteriology* 177(14):4121-4130.
78. Gyaneshwar P, *et al.* (2005) Lessons from Escherichia coli genes similarly regulated in response to nitrogen and sulfur limitation. *Proc Natl Acad Sci U S A* 102(9):3453-3458.
79. Hammar M, Arnqvist A, Bian Z, Olsen A, & Normark S (1995) Expression of two csg operons is required for production of fibronectin- and congo red-binding curli polymers in Escherichia coli K-12. *Molecular microbiology* 18(4):661-670.
80. Hammer BK & Bassler BL (2007) Regulatory small RNAs circumvent the conventional quorum sensing pathway in pandemic Vibrio cholerae. *Proceedings of the National Academy of Sciences of the United States of America* 104(27):11145-11149.
81. Hansen AM & Kaper JB (2009) Hfq affects the expression of the LEE pathogenicity island in enterohaemorrhagic Escherichia coli. *Molecular microbiology* 73(3):446-465.
82. Hao B, *et al.* (2013) Role of alternative sigma factor 54 (RpoN) from Vibrio anguillarum M3 in protease secretion, exopolysaccharide production, biofilm formation, and virulence. *Applied microbiology and biotechnology* 97(6):2575-2585.
83. Hardwidge PR, *et al.* (2005) Modulation of host cytoskeleton function by the enteropathogenic Escherichia coli and Citrobacter rodentium effector protein EspG. *Infection and immunity* 73(5):2586-2594.
84. Hastings JW & Nealson KH (1977) Bacterial bioluminescence. *Annual review of microbiology* 31:549-595.
85. He L, *et al.* (1993) PcnB is required for the rapid degradation of RNAI, the antisense RNA that controls the copy number of ColE1-related plasmids. *Molecular microbiology* 9(6):1131-1142.
86. Hershberg R, Altuvia S, & Margalit H (2003) A survey of small RNA-encoding genes in Escherichia coli. *Nucleic acids research* 31(7):1813-1820.
87. Hicks S, Frankel G, Kaper JB, Dougan G, & Phillips AD (1998) Role of intimin and bundle-forming pili in enteropathogenic Escherichia coli adhesion to pediatric intestinal tissue in vitro. *Infection and immunity* 66(4):1570-1578.

88. Hicks SW & Galan JE (2013) Exploitation of eukaryotic subcellular targeting mechanisms by bacterial effectors. *Nat Rev Microbiol* 11(5):316-326.
89. Hong SH, Wang X, O'Connor HF, Benedik MJ, & Wood TK (2012) Bacterial persistence increases as environmental fitness decreases. *Microbial biotechnology* 5(4):509-522.
90. Hughes DT, Clarke MB, Yamamoto K, Rasko DA, & Sperandio V (2009) The QseC adrenergic signaling cascade in enterohemorrhagic E. coli (EHEC). *PLoS Pathog* 5(8):e1000553.
91. Hughes DT, *et al.* (2010) Chemical sensing in mammalian host-bacterial commensal associations. *Proc Natl Acad Sci U S A* 107(21):9831-9836.
92. Ide T, *et al.* (2001) Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic Escherichia coli. *Cellular microbiology* 3(10):669-679.
93. Irizarry RA, *et al.* (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 4(2):249-264.
94. Iyoda S, *et al.* (2006) The GrlR-GrlA regulatory system coordinately controls the expression of flagellar and LEE-encoded type III protein secretion systems in enterohemorrhagic Escherichia coli. *Journal of bacteriology* 188(16):5682-5692.
95. Jarvis KG, *et al.* (1995) Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proceedings of the National Academy of Sciences of the United States of America* 92(17):7996-8000.
96. Jerse AE, Yu J, Tall BD, & Kaper JB (1990) A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. *Proc Natl Acad Sci U S A* 87(20):7839-7843.
97. Jimenez R, Cruz-Migoni SB, Huerta-Saquero A, Bustamante VH, & Puente JL (2010) Molecular characterization of GrlA, a specific positive regulator of ler expression in enteropathogenic Escherichia coli. *Journal of bacteriology* 192(18):4627-4642.
98. Joanny G, *et al.* (2007) Polyadenylation of a functional mRNA controls gene expression in Escherichia coli. *Nucleic acids research* 35(8):2494-2502.
99. Kailasan Vanaja S, Bergholz TM, & Whittam TS (2009) Characterization of the Escherichia coli O157:H7 Sakai GadE regulon. *Journal of bacteriology* 191(6):1868-1877.
100. Kalamorz F, Reichenbach B, Marz W, Rak B, & Gorke B (2007) Feedback control of glucosamine-6-phosphate synthase GlnS expression depends on the small RNA GlnZ and involves the novel protein Yhbj in Escherichia coli. *Molecular microbiology* 65(6):1518-1533.
101. Kanack KJ, Crawford JA, Tatsuno I, Karmali MA, & Kaper JB (2005) SepZ/EspZ is secreted and translocated into HeLa cells by the enteropathogenic Escherichia coli type III secretion system. *Infect Immun* 73(7):4327-4337.
102. Kaper JB, Nataro JP, & Mobley HL (2004) Pathogenic Escherichia coli. *Nature reviews. Microbiology* 2(2):123-140.
103. Karmali MA (1989) Infection by verocytotoxin-producing Escherichia coli. *Clinical microbiology reviews* 2(1):15-38.
104. Karpman D, *et al.* (1997) The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. *The Journal of infectious diseases* 175(3):611-620.

105. Kelley WL (2006) Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon. *Molecular microbiology* 62(5):1228-1238.
106. Kendall MM, Gruber CC, Parker CT, & Sperandio V (2012) Ethanolamine controls expression of genes encoding components involved in interkingdom signaling and virulence in enterohemorrhagic Escherichia coli O157:H7. *MBio* 3(3).
107. Kendall MM, Gruber CC, Rasko DA, Hughes DT, & Sperandio V (2011) Hfq virulence regulation in enterohemorrhagic Escherichia coli O157:H7 strain 86-24. *Journal of bacteriology* 193(24):6843-6851.
108. Kendall MM, Rasko DA, & Sperandio V (2010) The LysR-type regulator QseA regulates both characterized and putative virulence genes in enterohaemorrhagic Escherichia coli O157:H7. *Molecular microbiology* 76(5):1306-1321.
109. Kenny B, *et al.* (1997) Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. *Cell* 91(4):511-520.
110. Kenny B & Jepson M (2000) Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host mitochondria. *Cell Microbiol* 2(6):579-590.
111. Khine AA & Lingwood CA (1994) Capping and receptor-mediated endocytosis of cell-bound verotoxin (Shiga-like toxin). 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. *Journal of cellular physiology* 161(2):319-332.
112. Kim J, *et al.* (2007) The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function. *Cell host & microbe* 2(3):160-171.
113. Kim SH & Kim YH (2004) Escherichia coli O157:H7 adherence to HEp-2 cells is implicated with curli expression and outer membrane integrity. *Journal of veterinary science* 5(2):119-124.
114. Kint G, De Coster D, Marchal K, Vanderleyden J, & De Keersmaecker SC (2010) The small regulatory RNA molecule MicA is involved in Salmonella enterica serovar Typhimurium biofilm formation. *BMC microbiology* 10:276.
115. Kistler WM, Mulugeta S, & Mauro SA (2011) Detection of stx and stx genes in Pennsylvanian white-tailed deer. *Toxins* 3(6):640-646.
116. Knutton S, *et al.* (1998) A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. *The EMBO journal* 17(8):2166-2176.
117. Kresse AU, Rohde M, & Guzman CA (1999) The EspD protein of enterohemorrhagic Escherichia coli is required for the formation of bacterial surface appendages and is incorporated in the cytoplasmic membranes of target cells. *Infection and immunity* 67(9):4834-4842.
118. Lathem WW, *et al.* (2002) StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. *Molecular microbiology* 45(2):277-288.
119. Li H, *et al.* (2009) The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25(16):2078-2079.
120. Lindberg AA, *et al.* (1987) Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. *The Journal of biological chemistry* 262(4):1779-1785.

121. Little JW, Edmiston SH, Pacelli LZ, & Mount DW (1980) Cleavage of the Escherichia coli *lexA* protein by the *recA* protease. *Proceedings of the National Academy of Sciences of the United States of America* 77(6):3225-3229.
122. Lodato PB, Hsieh PK, Belasco JG, & Kaper JB (2012) The ribosome binding site of a mini-ORF protects a T3SS mRNA from degradation by RNase E. *Mol Microbiol* 86(5):1167-1182.
123. Lodato PB & Kaper JB (2009) Post-transcriptional processing of the LEE4 operon in enterohaemorrhagic Escherichia coli. *Molecular microbiology* 71(2):273-290.
124. Low AS, *et al.* (2006) Analysis of fimbrial gene clusters and their expression in enterohaemorrhagic Escherichia coli O157:H7. *Environmental microbiology* 8(6):1033-1047.
125. Lucchetti-Miganeh C, Burrowes E, Baysse C, & Ermel G (2008) The post-transcriptional regulator CsrA plays a central role in the adaptation of bacterial pathogens to different stages of infection in animal hosts. *Microbiology* 154(Pt 1):16-29.
126. Luzader DH, Clark DE, Gonyar LA, & Kendall MM (2013) EutR is a direct regulator of genes that contribute to metabolism and virulence in enterohemorrhagic Escherichia coli O157:H7. *Journal of bacteriology*.
127. Maddocks OD, Scanlon KM, & Donnenberg MS (2013) An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins. *mBio* 4(3):e00152-00113.
128. Mandal M & Breaker RR (2004) Gene regulation by riboswitches. *Nature reviews. Molecular cell biology* 5(6):451-463.
129. March SB & Ratnam S (1986) Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. *Journal of clinical microbiology* 23(5):869-872.
130. Marches O, *et al.* (2008) EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsonophagocytosis. *Cellular microbiology* 10(5):1104-1115.
131. McClure R, *et al.* (2013) Computational analysis of bacterial RNA-Seq data. *Nucleic acids research* 41(14):e140.
132. McCollum JT, *et al.* (2012) Multistate outbreak of Escherichia coli O157:H7 infections associated with in-store sampling of an aged raw-milk Gouda cheese, 2010. *Journal of food protection* 75(10):1759-1765.
133. McDaniel TK, Jarvis KG, Donnenberg MS, & Kaper JB (1995) A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. *Proceedings of the National Academy of Sciences of the United States of America* 92(5):1664-1668.
134. McNamara BP & Donnenberg MS (1998) A novel proline-rich protein, EspF, is secreted from enteropathogenic Escherichia coli via the type III export pathway. *FEMS Microbiol Lett* 166(1):71-78.
135. Mellies JL, Barron AM, & Carmona AM (2007) Enteropathogenic and Enterohemorrhagic Escherichia coli Virulence Gene Regulation. *Infect Immun* 75(9):4199-4210.
136. Mellies JL, Elliott SJ, Sperandio V, Donnenberg MS, & Kaper JB (1999) The Per regulon of enteropathogenic Escherichia coli : identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (Ler). *Molecular microbiology* 33(2):296-306.
137. Melton-Celsa AR & O'Brien AD (2003) Animal models for STEC-mediated disease. *Methods in molecular medicine* 73:291-305.

138. Merino E & Yanofsky C (2005) Transcription attenuation: a highly conserved regulatory strategy used by bacteria. *Trends in genetics : TIG* 21(5):260-264.
139. Merrick MJ (1993) In a class of its own--the RNA polymerase sigma factor sigma 54 (sigma N). *Molecular microbiology* 10(5):903-909.
140. Michael B, Smith JN, Swift S, Heffron F, & Ahmer BM (2001) SdiA of Salmonella enterica is a LuxR homolog that detects mixed microbial communities. *Journal of bacteriology* 183(19):5733-5742.
141. Michino H, *et al.* (1999) Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. *American journal of epidemiology* 150(8):787-796.
142. Miller JH (1972) *Experiments in molecular genetics* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
143. Miller ST, *et al.* (2004) Salmonella typhimurium recognizes a chemically distinct form of the bacterial quorum-sensing signal AI-2. *Molecular cell* 15(5):677-687.
144. Miyashita A, *et al.* (2012) Lipopolysaccharide O-antigen of enterohemorrhagic Escherichia coli O157:H7 is required for killing both insects and mammals. *FEMS microbiology letters* 333(1):59-68.
145. Mizuno T, Chou MY, & Inouye M (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). *Proceedings of the National Academy of Sciences of the United States of America* 81(7):1966-1970.
146. Mohanty BK & Kushner SR (2011) Bacterial/archaeal/organelle polyadenylation. *Wiley interdisciplinary reviews. RNA* 2(2):256-276.
147. Morita T, Mochizuki Y, & Aiba H (2006) Translational repression is sufficient for gene silencing by bacterial small noncoding RNAs in the absence of mRNA destruction. *Proceedings of the National Academy of Sciences of the United States of America* 103(13):4858-4863.
148. Mundy R, *et al.* (2004) Identification of a novel Citrobacter rodentium type III secreted protein, EspI, and roles of this and other secreted proteins in infection. *Infection and immunity* 72(4):2288-2302.
149. Narberhaus F, Waldminghaus T, & Chowdhury S (2006) RNA thermometers. *FEMS microbiology reviews* 30(1):3-16.
150. Nealson KH & Hastings JW (1979) Bacterial bioluminescence: its control and ecological significance. *Microbiological reviews* 43(4):496-518.
151. Neely MN & Friedman DI (1998) Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. *Molecular microbiology* 28(6):1255-1267.
152. Nennering AA, *et al.* (2011) CsgE is a curli secretion specificity factor that prevents amyloid fibre aggregation. *Molecular microbiology* 81(2):486-499.
153. Neves BC, *et al.* (2003) CesD2 of enteropathogenic Escherichia coli is a second chaperone for the type III secretion translocator protein EspD. *Infection and immunity* 71(4):2130-2141.
154. Njoroge J & Sperandio V (2012) Enterohemorrhagic Escherichia coli virulence regulation by two bacterial adrenergic kinases, QseC and QseE. *Infect Immun* 80(2):688-703.

155. Njoroge JW, Gruber C, & Sperandio V (2013) The Interacting Cra and KdpE Regulators Are Involved in the Expression of Multiple Virulence Factors in Enterohemorrhagic *Escherichia coli*. *Journal of bacteriology* 195(11):2499-2508.
156. Njoroge JW, Nguyen Y, Curtis MM, Moreira CG, & Sperandio V (2012) Virulence Meets Metabolism: Cra and KdpE Gene Regulation in Enterohemorrhagic *Escherichia coli*. *MBio* 3(5):e00280-00212.
157. Notley-McRobb L, King T, & Ferenci T (2002) rpoS mutations and loss of general stress resistance in *Escherichia coli* populations as a consequence of conflict between competing stress responses. *Journal of bacteriology* 184(3):806-811.
158. O'Connell CB, *et al.* (2004) SepL, a protein required for enteropathogenic *Escherichia coli* type III translocation, interacts with secretion component SepD. *Molecular microbiology* 52(6):1613-1625.
159. Ochman H, Lawrence JG, & Groisman EA (2000) Lateral gene transfer and the nature of bacterial innovation. *Nature* 405(6784):299-304.
160. Opdyke JA, Fozo EM, Hemm MR, & Storz G (2011) RNase III participates in GadY-dependent cleavage of the gadX-gadW mRNA. *Journal of molecular biology* 406(1):29-43.
161. Opdyke JA, Kang JG, & Storz G (2004) GadY, a small-RNA regulator of acid response genes in *Escherichia coli*. *Journal of bacteriology* 186(20):6698-6705.
162. Orchard RC & Alto NM (2012) Mimicking GEFs: a common theme for bacterial pathogens. *Cellular microbiology* 14(1):10-18.
163. Oshima T, *et al.* (2002) Transcriptome analysis of all two-component regulatory system mutants of *Escherichia coli* K-12. *Molecular microbiology* 46(1):281-291.
164. Ostroff SM, *et al.* (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in *Escherichia coli* O157:H7 infections. *The Journal of infectious diseases* 160(6):994-998.
165. Pacheco AR, *et al.* (2012) Fucose sensing regulates bacterial intestinal colonization. *Nature* 492(7427):113-117.
166. Pai CH, Kelly JK, & Meyers GL (1986) Experimental infection of infant rabbits with verotoxin-producing *Escherichia coli*. *Infection and immunity* 51(1):16-23.
167. Pallen MJ, Beatson SA, & Bailey CM (2005) Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: a Darwinian perspective. *FEMS microbiology reviews* 29(2):201-229.
168. Panos GZ, Betsi GI, & Falagas ME (2006) Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with *Escherichia coli* O157:H7 infection? *Alimentary pharmacology & therapeutics* 24(5):731-742.
169. Park CH, Gates KM, Vandel NM, & Hixon DL (1996) Isolation of Shiga-like toxin producing *Escherichia coli* (O157 and non-O157) in a community hospital. *Diagnostic microbiology and infectious disease* 26(2):69-72.
170. Pawar DM, Rossman ML, & Chen J (2005) Role of curli fimbriae in mediating the cells of enterohaemorrhagic *Escherichia coli* to attach to abiotic surfaces. *Journal of applied microbiology* 99(2):418-425.
171. Pereira CS, Thompson JA, & Xavier KB (2013) AI-2-mediated signalling in bacteria. *FEMS microbiology reviews* 37(2):156-181.

172. Pfeiffer V, Papenfort K, Lucchini S, Hinton JC, & Vogel J (2009) Coding sequence targeting by MicC RNA reveals bacterial mRNA silencing downstream of translational initiation. *Nature structural & molecular biology* 16(8):840-846.
173. Pickering LK, Obrig TG, & Stapleton FB (1994) Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli. *The Pediatric infectious disease journal* 13(6):459-475; quiz 476.
174. Plunkett G, 3rd, Rose DJ, Durfee TJ, & Blattner FR (1999) Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product. *Journal of bacteriology* 181(6):1767-1778.
175. Prevost K, et al. (2007) The small RNA RyhB activates the translation of shiA mRNA encoding a permease of shikimate, a compound involved in siderophore synthesis. *Molecular microbiology* 64(5):1260-1273.
176. Prigent-Combaret C, et al. (2001) Complex regulatory network controls initial adhesion and biofilm formation in Escherichia coli via regulation of the csgD gene. *Journal of bacteriology* 183(24):7213-7223.
177. Ptashne M (1967) Specific binding of the lambda phage repressor to lambda DNA. *Nature* 214(5085):232-234.
178. Radman M (1975) SOS repair hypothesis: phenomenology of an inducible DNA repair which is accompanied by mutagenesis. *Basic life sciences* 5A:355-367.
179. Rangel JM, Sparling PH, Crowe C, Griffin PM, & Swerdlow DL (2005) Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. *Emerging infectious diseases* 11(4):603-609.
180. Rasko DA, et al. (2008) Targeting QseC signaling and virulence for antibiotic development. *Science* 321(5892):1078-1080.
181. Reading NC, Rasko D, Torres AG, & Sperandio V (2010) A transcriptome study of the QseEF two-component system and the QseG membrane protein in enterohaemorrhagic Escherichia coli O157 : H7. *Microbiology* 156(Pt 4):1167-1175.
182. Reading NC, Rasko DA, Torres AG, & Sperandio V (2009) The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 106(14):5889-5894.
183. Reading NC, et al. (2007) A novel two-component signaling system that activates transcription of an enterohemorrhagic Escherichia coli effector involved in remodeling of host actin. *Journal of bacteriology* 189(6):2468-2476.
184. Reichenbach B, Gopel Y, & Gorke B (2009) Dual control by perfectly overlapping sigma 54- and sigma 70- promoters adjusts small RNA GlmY expression to different environmental signals. *Molecular microbiology* 74(5):1054-1070.
185. Reitzer L & Schneider BL (2001) Metabolic context and possible physiological themes of sigma(54)-dependent genes in Escherichia coli. *Microbiology and molecular biology reviews* : MMBR 65(3):422-444, table of contents.
186. Repoila F, Majdalani N, & Gottesman S (2003) Small non-coding RNAs, co-ordinators of adaptation processes in Escherichia coli: the RpoS paradigm. *Molecular microbiology* 48(4):855-861.

187. Riedl J, *et al.* (2008) Lifeact: a versatile marker to visualize F-actin. *Nature methods* 5(7):605-607.
188. Riley LW, *et al.* (1983) Hemorrhagic colitis associated with a rare Escherichia coli serotype. *The New England journal of medicine* 308(12):681-685.
189. Riordan JT, Tietjen JA, Walsh CW, Gustafson JE, & Whittam TS (2010) Inactivation of alternative sigma factor 54 (RpoN) leads to increased acid resistance, and alters locus of enterocyte effacement (LEE) expression in Escherichia coli O157 : H7. *Microbiology* 156(Pt 3):719-730.
190. Ritchie JM & Waldor MK (2005) The locus of enterocyte effacement-encoded effector proteins all promote enterohemorrhagic Escherichia coli pathogenicity in infant rabbits. *Infection and immunity* 73(3):1466-1474.
191. Roberts JW, Roberts CW, & Craig NL (1978) Escherichia coli recA gene product inactivates phage lambda repressor. *Proceedings of the National Academy of Sciences of the United States of America* 75(10):4714-4718.
192. Roxas JL, *et al.* (2012) The enteropathogenic Escherichia coli-secreted protein EspZ inhibits host cell apoptosis. *Infection and immunity* 80(11):3850-3857.
193. Rumbaugh KP, Griswold JA, Iglewski BH, & Hamood AN (1999) Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. *Infection and immunity* 67(11):5854-5862.
194. Russell RM, Sharp FC, Rasko DA, & Sperandio V (2007) QseA and GrIR/GrIA regulation of the locus of enterocyte effacement genes in enterohemorrhagic Escherichia coli. *Journal of bacteriology* 189(14):5387-5392.
195. Safdar N, Said A, Gangnon RE, & Maki DG (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. *JAMA : the journal of the American Medical Association* 288(8):996-1001.
196. Sambrook J, Fritsch EF, & Maniatis T (1989) *Molecular cloning: a laboratory manual* (Cold Spring Harbor Laboratory Press,, Cold Spring Harbor, NY).
197. Saxena SK, O'Brien AD, & Ackerman EJ (1989) Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. *The Journal of biological chemistry* 264(1):596-601.
198. Scallan E, *et al.* (2011) Foodborne illness acquired in the United States--major pathogens. *Emerging infectious diseases* 17(1):7-15.
199. Scheiring J, Andreoli SP, & Zimmerhackl LB (2008) Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). *Pediatric nephrology* 23(10):1749-1760.
200. Schmidt H, Beutin L, & Karch H (1995) Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933. *Infection and immunity* 63(3):1055-1061.
201. Schmidt H, Henkel B, & Karch H (1997) A gene cluster closely related to type II secretion pathway operons of gram-negative bacteria is located on the large plasmid of enterohemorrhagic Escherichia coli O157 strains. *FEMS microbiology letters* 148(2):265-272.
202. Sekiya K, *et al.* (2001) Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure. *Proc Natl Acad Sci U S A* 98(20):11638-11643.
203. Selyunin AS, *et al.* (2011) The assembly of a GTPase-kinase signalling complex by a bacterial catalytic scaffold. *Nature* 469(7328):107-111.

204. Shah D, *et al.* (2006) Persisters: a distinct physiological state of *E. coli*. *BMC microbiology* 6:53.
205. Shakhnovich EA, Davis BM, & Waldor MK (2009) Hfq negatively regulates type III secretion in EHEC and several other pathogens. *Molecular microbiology* 74(2):347-363.
206. Shames SR, *et al.* (2010) The pathogenic *E. coli* type III effector EspZ interacts with host CD98 and facilitates host cell pro-survival signalling. *Cellular microbiology* 12(9):1322-1339.
207. Sharma CM, Darfeuille F, Plantinga TH, & Vogel J (2007) A small RNA regulates multiple ABC transporter mRNAs by targeting C/A-rich elements inside and upstream of ribosome-binding sites. *Genes & development* 21(21):2804-2817.
208. Sharma VK & Zuerner RL (2004) Role of hha and ler in transcriptional regulation of the esp operon of enterohemorrhagic *Escherichia coli* O157:H7. *Journal of bacteriology* 186(21):7290-7301.
209. Sharp FC & Sperandio V (2007) QseA directly activates transcription of LEE1 in enterohemorrhagic *Escherichia coli*. *Infection and immunity* 75(5):2432-2440.
210. Shevchuk NA, *et al.* (2004) Construction of long DNA molecules using long PCR-based fusion of several fragments simultaneously. *Nucleic acids research* 32(2):e19.
211. Siegler RL, Pavia AT, Christofferson RD, & Milligan MK (1994) A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. *Pediatrics* 94(1):35-40.
212. Silhavy TJ & Beckwith JR (1985) Uses of lac fusions for the study of biological problems. *Microbiological reviews* 49(4):398-418.
213. Simons RW, Houman F, & Kleckner N (1987) Improved single and multicopy lac-based cloning vectors for protein and operon fusions. *Gene* 53(1):85-96.
214. Simons RW & Kleckner N (1983) Translational control of IS10 transposition. *Cell* 34(2):683-691.
215. Smith RS & Iglewski BH (2003) *P. aeruginosa* quorum-sensing systems and virulence. *Current opinion in microbiology* 6(1):56-60.
216. Sperandio V, Mellies JL, Nguyen W, Shin S, & Kaper JB (1999) Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America* 96(26):15196-15201.
217. Sperandio V, Torres AG, Giron JA, & Kaper JB (2001) Quorum sensing is a global regulatory mechanism in enterohemorrhagic *Escherichia coli* O157:H7. *Journal of bacteriology* 183(17):5187-5197.
218. Sperandio V, Torres AG, Jarvis B, Nataro JP, & Kaper JB (2003) Bacteria-host communication: the language of hormones. *Proc. Natl. Acad. Sci. USA* 100(15):8951-8956.
219. Sperandio V, Torres AG, & Kaper JB (2002) Quorum sensing *Escherichia coli* regulators B and C (QseBC): a novel two-component regulatory system involved in the regulation of flagella and motility by quorum sensing in *E. coli*. *Molecular microbiology* 43(3):809-821.
220. Staley TE, Jones EW, & Corley LD (1969) Attachment and penetration of *Escherichia coli* into intestinal epithelium of the ileum in newborn pigs. *Am J Pathol* 56(3):371-392.
221. Storz G, Vogel J, & Wassarman KM (2011) Regulation by small RNAs in bacteria: expanding frontiers. *Molecular cell* 43(6):880-891.

222. Stougaard P, Molin S, & Nordstrom K (1981) RNAs involved in copy-number control and incompatibility of plasmid R1. *Proceedings of the National Academy of Sciences of the United States of America* 78(10):6008-6012.
223. Strockbine NA, *et al.* (1986) Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. *Infection and immunity* 53(1):135-140.
224. Surette MG, Miller MB, & Bassler BL (1999) Quorum sensing in Escherichia coli, Salmonella typhimurium, and Vibrio harveyi: a new family of genes responsible for autoinducer production. *Proceedings of the National Academy of Sciences of the United States of America* 96(4):1639-1644.
225. Taga ME, Semmelhack JL, & Bassler BL (2001) The LuxS-dependent autoinducer AI-2 controls the expression of an ABC transporter that functions in AI-2 uptake in Salmonella typhimurium. *Molecular microbiology* 42(3):777-793.
226. Tatsuno I, *et al.* (2001) toxB gene on pO157 of enterohemorrhagic Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. *Infection and immunity* 69(11):6660-6669.
227. Tendeng C & Bertin PN (2003) H-NS in Gram-negative bacteria: a family of multifaceted proteins. *Trends in microbiology* 11(11):511-518.
228. Thanabalasuriar A, *et al.* (2010) The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli. *Cellular microbiology* 12(1):31-41.
229. Thony B & Hennecke H (1989) The -24/-12 promoter comes of age. *FEMS microbiology reviews* 5(4):341-357.
230. Timmermans J & Van Melderen L (2010) Post-transcriptional global regulation by CsrA in bacteria. *Cellular and molecular life sciences : CMLS* 67(17):2897-2908.
231. Tobe T, *et al.* (2006) An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. *Proceedings of the National Academy of Sciences of the United States of America* 103(40):14941-14946.
232. Tomizawa J, Itoh T, Selzer G, & Som T (1981) Inhibition of ColE1 RNA primer formation by a plasmid-specified small RNA. *Proceedings of the National Academy of Sciences of the United States of America* 78(3):1421-1425.
233. Tomson FL, *et al.* (2005) Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. *Molecular microbiology* 56(2):447-464.
234. Tramonti A, De Canio M, & De Biase D (2008) GadX/GadW-dependent regulation of the Escherichia coli acid fitness island: transcriptional control at the gadY-gadW divergent promoters and identification of four novel 42 bp GadX/GadW-specific binding sites. *Molecular microbiology* 70(4):965-982.
235. Trotochaud AE & Wassarman KM (2005) A highly conserved 6S RNA structure is required for regulation of transcription. *Nature structural & molecular biology* 12(4):313-319.
236. Tu X, Nisan I, Yona C, Hanski E, & Rosenshine I (2003) EspH, a new cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic Escherichia coli. *Mol Microbiol* 47(3):595-606.

237. Tyler JS, Mills MJ, & Friedman DI (2004) The operator and early promoter region of the Shiga toxin type 2-encoding bacteriophage 933W and control of toxin expression. *Journal of bacteriology* 186(22):7670-7679.
238. Urban JH & Vogel J (2008) Two seemingly homologous noncoding RNAs act hierarchically to activate glmS mRNA translation. *PLoS biology* 6(3):e64.
239. Vingadassalom D, *et al.* (2010) Enterohemorrhagic E. coli requires N-WASP for efficient type III translocation but not for EspFU-mediated actin pedestal formation. *PLoS pathogens* 6(8):e1001056.
240. Vogel J (2009) A rough guide to the non-coding RNA world of Salmonella. *Molecular microbiology* 71(1):1-11.
241. Vogel J & Sharma CM (2005) How to find small non-coding RNAs in bacteria. *Biological chemistry* 386(12):1219-1238.
242. Vogler AP, Trentmann S, & Lengeler JW (1989) Alternative route for biosynthesis of amino sugars in Escherichia coli K-12 mutants by means of a catabolic isomerase. *Journal of bacteriology* 171(12):6586-6592.
243. Wadolkowski EA, Burris JA, & O'Brien AD (1990) Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. *Infection and immunity* 58(8):2438-2445.
244. Wainwright LA & Kaper JB (1998) EspB and EspD require a specific chaperone for proper secretion from enteropathogenic Escherichia coli. *Molecular microbiology* 27(6):1247-1260.
245. Walters M, Sircili MP, & Sperandio V (2006) AI-3 synthesis is not dependent on luxS in Escherichia coli. *J Bacteriol* 188(16):5668-5681.
246. Walters M, Sircili MP, & Sperandio V (2006) AI-3 synthesis is not dependent on luxS in Escherichia coli. *Journal of bacteriology* 188(16):5668-5681.
247. Walters M & Sperandio V (2006) Quorum sensing in Escherichia coli and Salmonella. *International journal of medical microbiology : IJMM* 296(2-3):125-131.
248. Wang D, Roe AJ, McAteer S, Shipston MJ, & Gally DL (2008) Hierarchical type III secretion of translocators and effectors from Escherichia coli O157:H7 requires the carboxy terminus of SepL that binds to Tir. *Molecular microbiology* 69(6):1499-1512.
249. Wassarman KM (2007) 6S RNA: a small RNA regulator of transcription. *Current opinion in microbiology* 10(2):164-168.
250. Wassarman KM & Saecker RM (2006) Synthesis-mediated release of a small RNA inhibitor of RNA polymerase. *Science* 314(5805):1601-1603.
251. Waters LS & Storz G (2009) Regulatory RNAs in bacteria. *Cell* 136(4):615-628.
252. Whitehead NA, Barnard AM, Slater H, Simpson NJ, & Salmond GP (2001) Quorum-sensing in Gram-negative bacteria. *FEMS microbiology reviews* 25(4):365-404.
253. Widgren S, *et al.* (2013) Environmental sampling for evaluating verotoxigenic Escherichia coli O157: H7 status in dairy cattle herds. *Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc* 25(2):189-198.
254. Wiles S, *et al.* (2004) Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium. *Cellular microbiology* 6(10):963-972.

255. Wilson RK, Shaw RK, Daniell S, Knutton S, & Frankel G (2001) Role of EscF, a putative needle complex protein, in the type III protein translocation system of enteropathogenic *Escherichia coli*. *Cellular microbiology* 3(11):753-762.
256. Wong AR, Clements A, Raymond B, Crepin VF, & Frankel G (2012) The interplay between the *Escherichia coli* Rho guanine nucleotide exchange factor effectors and the mammalian RhoGEF inhibitor EspH. *mBio* 3(1).
257. Wright PR, *et al.* (2013) Comparative genomics boosts target prediction for bacterial small RNAs. *Proceedings of the National Academy of Sciences of the United States of America* 110(37):E3487-3496.
258. Wu B, *et al.* (2010) NleG Type 3 effectors from enterohaemorrhagic *Escherichia coli* are U-Box E3 ubiquitin ligases. *PLoS pathogens* 6(6):e1000960.
259. Xicohtencatl-Cortes J, *et al.* (2009) The type 4 pili of enterohemorrhagic *Escherichia coli* O157:H7 are multipurpose structures with pathogenic attributes. *Journal of bacteriology* 191(1):411-421.
260. Xu F, Lin-Chao S, & Cohen SN (1993) The *Escherichia coli* pcnB gene promotes adenylation of antisense RNAI of ColE1-type plasmids in vivo and degradation of RNAI decay intermediates. *Proceedings of the National Academy of Sciences of the United States of America* 90(14):6756-6760.
261. Yamamoto K, *et al.* (2005) Functional characterization in vitro of all two-component signal transduction systems from *Escherichia coli*. *The Journal of biological chemistry* 280(2):1448-1456.
262. Yang T, Echols M, Martin A, & Bar-Peled M (2010) Identification and characterization of a strict and a promiscuous N-acetylglucosamine-1-P uridylyltransferase in *Arabidopsis*. *The Biochemical journal* 430(2):275-284.
263. Zhang L, *et al.* (2004) Regulators encoded in the *Escherichia coli* type III secretion system 2 gene cluster influence expression of genes within the locus for enterocyte effacement in enterohemorrhagic *E. coli* O157:H7. *Infection and immunity* 72(12):7282-7293.
264. Zhao S, *et al.* (2013) The N-terminal domain of EspF induces host cell apoptosis after infection with enterohaemorrhagic *Escherichia coli* O157:H7. *PloS one* 8(1):e55164.